

Supporting information

Pyrimido[5,4-*e*]azolo[1,5-*a*]pyrimidines and pyrimido[4,5-*e*][1,2,4]triazolo [5,1-*c*][1,2,4]triazines: one-pot multi-component synthesis and cytotoxic activity

Eva V. Bersneva,^a Konstantin V. Savateev,^{*a} Pavel A. Slepukhin,^b Vsevolod V.
Melekhin,^{a,c} Maria D. Tohtueva,^a Vladimir L. Rusinov^{a,b}

^aUral Federal University named after the First President of Russia B.N. Eltsin,
Mira st. 19, Yekaterinburg, 620002, Russian Federation


^bInstitute of Organic Synthesis of the Ural Branch of the Russian Academy of
Science, Sofii Kovalevskoy st. 22, Yekaterinburg, 620137, Russian Federation

^cDepartment of Medical Biology and Genetics, Ural State Medical University,
Yekaterinburg, Russian Federation

Contents

Contents 1 Optimization of reaction conditions for conversion of amino-ethoxycarbonyl- azoloazines to pyrimidoazoloazines.....	S2
Contents 2. Optimization of reaction conditions for conversion of amino-cyano-azoloazines to pyrimidoazoloazines.....	S3
Contents 3. Experimental part. Synthesis.....	S4
Contents 4. X-Ray Crystal Structure Analysis.....	S27
Contents 5. Cytotoxicity assay.....	S28
Contents 6. NMR, IR, mass-spectrometry data for obtained heterocycles.....	S29

Optimization of reaction conditions for conversion of amino-ethoxycarbonyl-azoloazines to pyrimidoazoloazines

									
№	X	AcOH, equiv.	HC(OEt) ₃ , equiv.	n- BuNH ₂ , equiv.	Solvent	Conditions	T, °C	Time, h	Yield, %
1	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	79
2	N	3	3	3	1,4-Dioxane	Round-bottom flask	reflux	8	69
3	N	3	3	3	CH ₃ CN	Round-bottom flask	reflux	8	19
4	N	3	3	3	PhCH ₃	Autoclave	140	8	80
5	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	15	80
6	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	4	53
7	N	3	3	1	PhCH ₃	Round-bottom flask	reflux	8	47
8	N	3	50	1	-	Round-bottom flask	reflux	8	0
9	N	1	3	1	PhCH ₃	Round-bottom flask	reflux	8	45
10	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	0 ^[b]
11	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	0 ^[d]
12	CH	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	0
13	CH	3	3	3	PhCH ₃	Autoclave	120	8	20
14	CH	3	3	3	PhCH ₃	Autoclave	140	8	35
15	CH	3	3	3	CH ₃ CN	Autoclave	120	8	0
16	CH	3	3	3	1,4-Dioxane	Autoclave	160	8	57
17	CH	3	3	3	1,4-Dioxane	Autoclave	160	16	86
18	CH	3	3	1	1,4-Dioxane	Autoclave	160	8	0
19	CH	3	3	3	1,4-Dioxane	Autoclave	160	8	0 ^[b]
20	CH	3	3	3	1,4-Dioxane	Autoclave	160	8	0 ^[c]

^[a] – all reactions were carried out with 1 mmol of the starting heterocycle; ^[b] - MeC(OEt)₃ instead of HC(OEt)₃; ^[c] - ZnCl₂ instead of AcOH; ^[d] - PhC(OEt)₃ instead of HC(OEt)₃

**Optimization of reaction conditions for conversion of amino-cyano-azoloazines to
pyrimidoazoloazines**


$\xrightarrow[\text{solvent, temperature}]{\begin{matrix} \text{HC(OEt)}_3 \\ \text{AcOH} \\ n\text{-BuNH}_2 \end{matrix}}$									
№	X	AcOH, equiv.	HC(OEt) ₃ , equiv.	n- BuNH ₂ , equiv.	Solvent	Conditions	T, °C	Time, h	Yield, %
1	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	96
2	N	3	3	1	PhCH ₃	Round-bottom flask	reflux	8	81
3	N	3	3	3	1,4-Dioxane	Round-bottom flask	reflux	8	78
4	N	3	3	3	PhCH ₃	Round-bottom flask	reflux	3	85
5	N	3	3	1	1,4-Dioxane	Round-bottom flask	reflux	8	71
6	N	3	3	1	PhCH ₃	Autoclave	140	8	83
7	N	3	3	3	PhCH ₃	Autoclave	160	12	0 ^[b]
8	N	-	-	-	Formamide	Round-bottom flask	reflux	8	0 ^[c]
9	CH	3	3	3	PhCH ₃	Round-bottom flask	reflux	8	14
10	CH	3	3	3	1,4-Dioxane	Autoclave	160	8	60
11	CH	3	3	3	PhCH ₃	Autoclave	140	8	75
12	CH	3	3	3	PhCH ₃	Autoclave	140	12	87
13	CH	3	3	1	PhCH ₃	Autoclave	140	8	31
14	CH	3	3	3	PhCH ₃	Autoclave	160	12	0 ^[b]

^[a] – all reactions were carried out with 1 mmol of the starting heterocycle; ^[b] - PhC(OEt)₃ instead of HC(OEt)₃; ^[c] – conditions according to ref. 18

Materials and Methods. Commercial reagents were obtained from Sigma-Aldrich, Acros Organics, Macklin, or Alfa Aesar and used without any preprocessing. All workup and purification procedures were carried out using analytical-grade solvents. One-dimensional ^1H , ^{13}C , ^{15}N NMR spectra were acquired on a Bruker DRX-400 instrument (400, 101, 400 MHz, respectively) or a Bruker Avance NEO 600 instrument (600, 151, 600 MHz, respectively), equipped with a Prodigy broadband gradient cryoprobe, utilizing DMSO- d_6 and CDCl_3 as a solvents. Chemical shifts are expressed in δ (parts per million, ppm) values, and coupling constants are expressed in herts (Hz). The following abbreviations are used for the multiplicity of NMR signals: br., broadened; s, singlet; d, doublet; t, triplet; and m, multiplet. IR spectra were recorded on a Bruker α spectrometer equipped with a ZnSe ATR accessory. Elemental analysis was performed on a PerkinElmer PE 2400 elemental analyzer. Mass spectra were recorded with a Shimadzu GCMS-QP 2010 “Ultra” (Kyoto, Japan) mass spectrometer using the electron impact (EI) ionization technique (40-200 °C, 70 eV). Electrospray mass spectra (HRMS) were recorded in positive ionization mode using qTOF Bruker maXis Impact HD instrument. Melting points were determined on a Stuart SMP-3 (Staffordshire, UK) and are uncorrected. The monitoring of the reaction progress was performed using TLC on Silufol UV254 plates. The XRD analyses were carried out using equipment of the Center for Joint Use “Spectroscopy and Analysis of Organic Compounds” at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch). The experiment was accomplished on the automated X-ray diffractometer «Xcalibur 3» with CCD detector on the standard procedure (MoK α -irradiation, graphite monochromator, ω -scans with 1° step). For the XRD analyses the empirical absorption correction was applied. The solution and refinement of the structures were accomplished with using Olex2 program package.⁴¹ The structures were solved by method of the intrinsic phases in ShelXT program and refined by ShelXL by full-matrix least-squared method for non-hydrogen atoms. The H-atoms at the C-H bonds were placed in the calculated positions, H-atoms of the N-H bonds were solved by direct method and were refined independently in the isotropic approximation. Deposition Numbers CCDC 2401392 (for **23d**), contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe <http://www.ccdc.cam.ac.uk/structures>.

General method for the synthesis of pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one 19a-h.


Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.), appropriate amine (0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 4-amino-3-ethoxycarbonyl-7-methylsulfanyl[1,2,4]triazolo[5,1-*c*][1,2,4]triazine **17a** (0.254 g, 0.001 mol) in toluene (7 mL). The resulting mixture was refluxed for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).



7-Propyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19a).


Light brown powder (166 mg, 60% yield). *R_f* (AcOEt) = 0.7. M.p. = 195 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.02 (s, C8H, H); 4.13 (t, *J* = 7.4 Hz, CH₂, 2H); 2.80 (s, S-CH₃, 3H); 1.80–1.90 (m, CH₂, 2H); 1.01 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 170.5, 157.82, 157.78, 157.3, 140.2, 129.2, 48.8, 21.6, 13.6, 10.6. IR, ν, cm⁻¹: 3054, 2966, 2935, 2877, 2839, 1705, 1607, 1577, 1530, 1469, 1438, 1413, 1380, 1359, 1340, 1306, 1277, 12643, 1231, 1202, 1115, 1094, 1038, 1007, 984, 969, 901, 847, 801, 738, 708, 683, 655, 589, 566, 554, 524, 510. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₁N₇OS, 277; found C₁₀H₁₁N₇OS, 277. Anal. Calcd. For C₁₀H₁₁N₇OS: C, 43.31; H, 4.00; N, 35.36; found: C, 43.33; H, 3.92; N, 35.45

7-Isopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19b).




Light brown powder (149 mg, 54% yield). *R_f* (AcOEt) = 0.7. M.p. = 203 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.08 (s, C8H, H); 5.04–5.10 (m, NCH, H); 2.78 (s, S-CH₃, 3H); 1.52 (d, *J* = 6.8 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 170.5, 157.8, 157.1, 155.9, 139.7, 129.0, 48.7, 21.0, 13.6. IR, ν, cm⁻¹: 3065, 2981, 2964, 2939, 1772, 1708, 1581, 1529, 1469, 1422, 1413, 1376, 1350, 1339, 1315, 1280, 1247, 1193, 1177, 1128, 1115, 1094, 997, 971, 881, 831, 799, 752, 729, 706, 679, 638, 623, 592, 558, 544, 506. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₁N₇OS, 277; found C₁₀H₁₁N₇OS, 277. Anal. Calcd. For C₁₀H₁₁N₇OS: C, 43.31; H, 4.00; N, 35.36; found: C, 43.25; H, 3.96; N, 35.29

7-Cyclopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19c).




Light brown powder (247 mg, 90% yield). R_f (AcOEt) = 0.7. M.p. = 221 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (*J*, Hz): 8.88 (s, C8H, H); 3.40–3.46 (m, NCH, H); 2.80 (s, S-CH₃, 3H); 1.12–1.20 (m, 2CH₂, 4H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 170.6, 158.2, 158.1, 157.8, 139.8, 128.8, 30.6, 13.6, 6.0. IR, ν , cm⁻¹: 3194, 3149, 3081, 1717, 1659, 1599, 1570, 1552, 1538, 1503, 1467, 1455, 1426, 1366, 1340, 1304, 1273, 1264, 1228, 1192, 1164, 1124, 1103, 1072, 1033, 1003, 977, 967, 939, 873, 833, 822, 800, 781, 728, 708, 681, 659, 589, 571, 547, 517. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₉N₇OS, 275; found C₁₀H₉N₇OS, 275. Anal. Calcd. For C₁₀H₉N₇OS: C, 43.63; H, 3.30; N, 35.62; found: C, 43.57; H, 3.20; N, 35.66

7-Butyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19d).



Light brown powder (233 mg, 80% yield). R_f (AcOEt) = 0.7. M.p. = 216 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (*J*, Hz): 9.02 (s, C8H, H); 4.16 (t, *J* = 7.4 Hz, NCH₂, 2H); 2.8 (s, S-CH₃, 3H); 1.76–1.83 (2H, m, CH₂); 1.39–1.48 (m, CH₂, 2H); 1.00 (t, *J* = 7.4 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 171.0, 158.31, 158.25, 157.8, 140.7, 129.6, 47.6, 30.9, 19.6, 14.1, 14.0. IR, ν , cm⁻¹: 3063, 3013, 2958, 2934, 2872, 1717, 1574, 1526, 1469, 1433, 1409, 1382, 1369, 1351, 1337, 1308, 1284, 1258, 1217, 1192, 1170, 1119, 1101, 1018, 998, 990, 934, 802, 736, 705, 692, 653, 587, 554, 504. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₃N₇OS, 291; found C₁₁H₁₃N₇OS, 291. Anal. Calcd. For C₁₁H₁₃N₇OS: C, 45.35; H, 4.50; N, 33.65; found: C, 45.35; H, 4.53; N, 35.81

7-Isobutyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19e).




Light brown powder (201 mg, 69% yield). R_f (AcOEt) = 0.7. M.p. = 215 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (*J*, Hz): 8.99 (s, C8H, H); 3.99 (d, *J* = 7.4 Hz, CH₂, 2H); 2.80 (s, S-CH₃, 3H); 2.18–2.25 (m, CH, H); 1.00 (d, *J* = 6.7 Hz, 2CH₃, 6H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 170.5, 157.8 (2C), 157.4, 140.2, 129.2, 53.8 27.3, 19.4, 13.6. IR, ν , cm⁻¹: 3066, 2957, 2927, 2875, 1697, 1679, 1530, 1472, 1424, 1405, 1378, 1351, 1337, 1319, 1311, 1274, 1225, 1198, 1112, 1098, 1008, 988, 966, 916, 899, 820, 800, 754, 737, 705, 682, 661, 590, 563, 522. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₃N₇OS, 291; found C₁₁H₁₃N₇OS, 291. Anal. Calcd. For C₁₁H₁₃N₇OS: C, 45.35; H, 4.50; N, 33.65; found: C, 45.42; H, 4.38; N, 35.61

7-(4-Hydroxybutyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19g).



Light brown powder (34 mg, 11% yield). R_f (AcOEt) = 0.7. M.p. = 223 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.03 (s, C8H, H); 4.32 (s, OH, H); 4.18 (t, J = 7.2 Hz, NCH₂, 2H); 3.48 (t, J = 6.2 Hz, OCH₂, 2H); 2.80 (s, S-CH₃, 3H); 1.82–1.90 (m, CH₂, 2H); 1.50–1.57 (m, CH₂, 2H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 170.5, 157.9, 157.8, 157.3, 140.3, 129.2, 60.2, 47.4, 29.3, 25.3, 13.7. IR, ν , cm⁻¹: 3487, 1694, 1654, 1630, 1584, 1536, 1470, 1377, 1353, 1338, 1311, 1280, 1211, 1180, 1138, 1085, 1056, 1022, 988, 909, 803, 770, 728, 709, 651, 593, 515. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₃N₇O₂S, 307; found C₁₁H₁₃N₇O₂S, 307. Anal. Calcd. For C₁₁H₁₃N₇O₂S: C, 42.99; H, 4.26; N, 31.90; found: C, 43.05; H, 4.39; N, 32.00. HRMS (ESI, Q-TOF), m/z : [M+H]⁺ Calculated for C₁₁H₁₃N₇O₂S⁺ 308.0924. Found 308.0927

7-(4-Chlorophenethyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19h).




Light brown powder (227 mg, 61% yield). R_f (AcOEt) = 0.7. M.p. = 265 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 8.79 (s, C8H, H); 7.31 (s, 4CH, 4H); 4.38 (t, J = 7.4 Hz, NCH₂, 2H); 3.12 (t, J = 7.4 Hz, CH₂, 2H); 2.79 (s, S-CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 170.6, 157.9, 157.5, 157.2, 140.1, 136.3, 131.4, 130.9, 129.0, 128.5, 48.3, 33.2, 13.6. IR, ν , cm⁻¹: 3044, 2937, 1703, 1574, 1523, 1490, 1469, 1456, 1406, 1378, 1362, 1338, 1301, 1271, 1255, 1213, 1186, 1131, 1113, 1088, 1041, 1006, 979, 863, 842, 819, 800, 743, 707, 657, 590, 563, 551, 519. MS (EI, 70 eV), m/z : Calcd for: C₁₅H₁₂Cl³⁵N₇OS, 373; found C₁₅H₁₂Cl³⁵N₇OS, 373. Anal. Calcd. For C₁₅H₁₂ClN₇OS: C, 48.19; H, 3.24; N, 26.23; found: C, 48.10; H, 3.11; N, 26.35

General method for the synthesis of 7-propyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one 20a-e, 20h.


Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.), appropriate amine (0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 7-amino-6-ethoxycarbonyl-2-(methylthio)[1,2,4]triazolo[1,5-*a*]pyrimidine **18a** (0.253 g, 0.001 mol) in 1,4-dioxane (7 mL). The resulting mixture was heated in autoclave at 160 °C for 15-20 hours until disappearance of the starting material by TLC analysis. The resulting mixture was cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).

7-Propyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20a).




White powder (229 mg, 83% yield). *R_f* (AcOEt) = 0.4. M.p. = 231-232 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.26 (s, C5H, H); 8.97 (s, C8H, H); 4.06 (t, *J* = 7.4 Hz, NCH₂, 2H); 2.72 (s, S-CH₃, 3H); 1.77–1.83 (m, CH₂, 2H); 0.98 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.2, 158.5, 157.5, 157.4, 153.9, 149.2, 104.8, 48.4, 21.7, 13.4, 10.6. IR, ν, cm⁻¹: 3040, 3007, 2959, 2937, 2868, 2817, 1691, 1600, 1556, 1502, 1440, 1421, 1388, 1371, 1357, 1349, 1333, 1311, 1294, 1276, 1252, 1225, 1183, 1120, 1098, 1085, 1050, 999, 980, 967, 951, 888, 875, 833, 798, 784, 753, 738, 709, 688, 648, 624, 616, 569, 557, 545, 511. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₂N₆OS, 276; found C₁₁H₁₂N₆OS, 276. Anal. Calcd. For C₁₁H₁₂N₆OS: C, 47.81; H, 4.38; N, 30.41; found: C, 47.81; H, 4.23; N, 30.33

7-Isopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20b).




White powder (94 mg, 34% yield). *R_f* (AcOEt) = 0.45. M.p. = 257-258 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.26 (s, C5H, H); 9.00 (s, C8H, H); 4.99–5.06 (m, NCH, H); 2.72 (s, S-CH₃, 3H); 1.53 (d, *J* = 7.2 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.1, 158.2, 157.4, 155.5, 154.1, 148.8, 104.7, 48.1, 21.0, 13.4. IR, ν, cm⁻¹: 3048, 2981, 1694, 1655, 1602, 1555, 1501, 1454, 1417, 1395, 1369, 1349, 1309, 1292, 1277, 1251, 1235, 1222, 1189, 1136, 1118, 1112, 1080, 1033, 996, 978, 969, 953, 939, 931, 909, 901, 884, 826, 795, 756, 737, 688, 667, 640, 568, 555, 539, 527, 513. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₂N₆OS, 276; found C₁₁H₁₂N₆OS, 276. Anal. Calcd. For C₁₁H₁₂N₆OS: C, 47.81; H, 4.38; N, 30.41; found: C, 47.69; H, 4.20; N, 30.35

7-Cyclopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20c).




White powder (170 mg, 62% yield). R_f (AcOEt) = 0.35. M.p. = 229–230 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.25 (s, C5H, H); 8.82 (s, C8H, H); 3.33–3.39 (m, NCH, H); 2.71 (s, S-CH₃, 3H); 1.12–1.17 (m, CH₂, 2H); 1.06–1.10 (m, CH₂, 2H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 168.3, 159.4, 157.7, 157.4, 153.8, 148.8, 104.4, 30.2, 13.4, 5.8. IR, ν , cm⁻¹: 3084, 3053, 2932, 1699, 1592, 1550, 1495, 1426, 1397, 1371, 1360, 1340, 1316, 1287, 1275, 1249, 1209, 1175, 1101, 1070, 1052, 1004, 993, 976, 969, 955, 939, 876, 838, 815, 795, 770, 754, 738, 710, 688, 675, 662, 563, 545. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₀N₆OS, 274; found C₁₁H₁₀N₆OS, 274. Anal. Calcd. For C₁₁H₁₀N₆OS: C, 48.17; H, 3.67; N, 30.64; found: C, 48.15; H, 3.67; N, 30.59

7-Butyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20d).



White powder (249 mg, 86% yield). R_f (AcOEt) = 0.45. M.p. = 190–191 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.26 (s, C5H, H); 8.97 (s, C8H, H); 4.08 (t, J = 7.2 Hz, NCH₂, 2H); 2.72 (s, S-CH₃, 3H); 1.71–1.78 (m, CH₂, 2H); 1.35–1.45 (m, CH₂, 2H); 0.98 (t, J = 7.4 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 168.2, 158.4, 157.5, 157.4, 153.9, 149.2, 104.8, 46.7, 30.4, 19.1, 13.5, 13.4. IR, ν , cm⁻¹: 3055, 2960, 2929, 2872, 2855, 1963, 1691, 1605, 1556, 1502, 1427, 1390, 1369, 1343, 1295, 1277, 1257, 1233, 1181, 1124, 1097, 1062, 1054, 1019, 987, 973, 949, 883, 837, 820, 797, 762, 749, 710, 689, 650, 623, 611, 592, 571, 549, 522, 515, 506. MS (EI, 70 eV), m/z : Calcd for: C₁₂H₁₄N₆OS, 290; found C₁₂H₁₄N₆OS, 290. Anal. Calcd. For C₁₂H₁₄N₆OS: C, 49.64; H, 4.86; N, 28.95; found: C, 49.69; H, 4.90; N, 29.09


7-Isobutyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20e).



White powder (235 mg, 81% yield). R_f (AcOEt) = 0.55. M.p. = 227–228 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.26 (s, C5H, H); 8.94 (s, C8H, H); 3.92 (d, J = 7.4 Hz, NCH₂, 2H); 2.72 (s, S-CH₃, 3H); 2.13–2.19 (m, CH₂CH, H); 0.97 (d, J = 6.7 Hz, 2CH₃, 6H). ^{13}C NMR (150 MHz, DMSO- d_6), δ , ppm.: 168.2, 158.7, 157.6, 157.5, 154.0, 149.2, 104.9, 53.4, 27.4, 19.4, 13.4. IR, ν , cm⁻¹: 3039, 2979, 2957, 2928, 1967, 1693, 1655, 1601, 1558, 1502, 1474, 1455, 1443, 1434, 1425, 1388, 1374, 1363, 1350, 1334, 1296, 1278, 1254, 1229, 1188, 1168, 1121, 1101, 1063, 1052, 1016, 992, 972, 951, 934, 884, 819, 794, 773, 748, 704, 688, 668, 653, 617, 603, 580, 565, 550, 541, 533, 513, 503. MS (EI, 70 eV), m/z : Calcd for:

C₁₂H₁₄N₆OS, 290; found C₁₂H₁₄N₆OS, 290. Anal. Calcd. For C₁₂H₁₄N₆OS: C, 49.64; H, 4.86; N, 28.95; found: C, 49.70; H, 4.92; N, 29.00

7-(4-Chlorophenethyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20h).




White powder (201 mg, 54% yield). *R_f* (AcOEt) = 0.50. M.p. = 271 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.30 (s, C5H, H); 8.72 (s, C8H, H); 7.35 (d, *J* = 8.4 Hz, 2CH, 2H); 7.28 (d, *J* = 8.4 Hz, 2CH, 2H); 4.29 (t, *J* = 7.2 Hz, NCH₂, 2H); 3.05 (t, *J* = 7.2 Hz, CH₂, 2H); 2.69 (s, S-CH₃, 3H). ¹³C

NMR (150 MHz, DMSO-*d*₆), δ, ppm.: 168.3, 158.4, 157.5, 157.3, 154.0, 149.2, 136.4, 131.4, 130.9, 128.6, 104.8, 48.0, 33.3, 13.4. IR, ν, cm⁻¹: 3304, 3236, 3199, 3079, 3057, 3026, 2980, 2949, 2929, 2905, 2870, 2843, 2804, 1695, 1606, 1558, 1504, 1426, 1408, 1385, 1367, 1345, 1304, 1282, 1253, 1229, 1142, 1091, 1063, 1015, 988, 861, 832, 812, 797, 748, 715, 654, 613, 588, 552, 536, 517. MS (EI, 70 eV), *m/z*: Calcd for: C₁₆H₁₃Cl³⁵N₆OS, 372, C₁₆H₁₃Cl³⁷N₆OS, 374; found C₁₆H₁₃Cl³⁵N₆OS, 372, C₁₆H₁₃Cl³⁷N₆OS, 374. Anal. Calcd. For C₁₆H₁₃ClN₆OS: C, 51.55; H, 3.51; N, 22.54; found: C, 51.74; H, 3.69; N, 22.44. HRMS (ESI, Q-TOF), *m/z*: [M+H]⁺ Calculated for C₁₆H₁₄ClN₆OS⁺ 373.0633. Found 373.0635

General method for the synthesis of *N*-butyl[1,2,4]triazoloazinecarboximidamide 21d, 22d.

n-Butylamine (0.300 mL, 0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of appropriate cyano[1,2,4]triazoloazine **17b/18b** (0.001 mol) in toluene (7 mL). The resulting mixture was heated at 140 °C in autoclave for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).


4-Amino-*N*-butyl-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazine-3-carboximidamide (21d)



Pink powder (252 mg, 90% yield). *R_f* (AcOEt) = 0.35. M.p. = 196 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 11.20 (s, NH, H); 9.77 (br.s, NH, H); 7.82 (br.s, NH₂, 2H); 3.41 (t, *J* = 7.4 Hz, NCH₂, 2H); 2.62 (s, S-CH₃,

3H); 1.58–1.63 (m, CH₂, 2H); 1.35–1.42 (m, CH₂, 2H); 0.91 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 165.0, 158.9, 156.2, 143.8, 120.8, 41.4, 30.0, 19.5, 13.6, 13.4. IR, ν, cm⁻¹: 2958, 2926, 2890, 2885, 2833, 2812, 1663, 1623, 1558, 1505, 1444, 1415, 1388, 1285, 1248, 1200, 1171, 1045, 967, 938, 883, 821, 763, 738, 687, 651, 630, 605, 545, 531, 523, 512. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₆N₈S, 280; found C₁₀H₁₆N₈S, 280. Anal. Calcd. For C₁₀H₁₆N₈S: C, 42.84; H, 5.75; N, 39.97; found: C, 42.88; H, 5.75; N, 40.01

7-Amino-*N*-butyl-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboximidamide (22d).




The crude product was recrystallized from EtOH. Beige powder (128 mg, 46% yield). R_f (AcOEt) = 0.1. M.p. = 204 °C. ^1H NMR (600 MHz, DMSO- d_6), δ , ppm. (J , Hz): 11.69 (s, NH, H); 8.60 (s, C5H, H); 8.17 (s, NH₂, 2H);

7.32 (s, NH, H); 4.34 (t, J = 5.2 Hz, OH, H); 3.41–3.47 (m, NCH₂, 2H); 3.31 (q, J = 7.2 Hz, OCH₂, 2H); 2.59 (s, S-CH₃, 3H); 1.57–1.64 (m, CH₂, 2H); 1.36–1.46 (m, CH₂, 2H); 1.05 (t, J = 7.2 Hz, OCH₂CH₃, 3H); 0.93 (t, J = 7.4 Hz, CH₃, 3H). ^{13}C NMR (150 MHz, DMSO- d_6), δ , ppm.: 163.7, 159.2, 156.2, 152.2, 150.1, 91.4, 56.0, 41.8, 30.3, 19.7, 18.6, 13.6, 13.3. IR, ν , cm⁻¹: 3316, 3133, 2956, 2930, 2866, 2818, 1692, 1632, 1554, 1519, 1469, 1437, 1396, 1320, 1263, 1230, 1176, 1127, 1092, 1052, 993, 969, 951, 885, 839, 822, 767, 715, 688, 650, 603, 564, 514. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₇N₇SxEtOH, 279; found C₁₁H₁₇N₇S, 279. Anal. Calcd. For C₁₁H₁₇N₇SxH₂O: C, 47.98; H, 7.12; N, 30.13; found: C, 48.01; H, 7.06; N, 30.19. HRMS (ESI, Q-TOF), m/z : [M+H]⁺ Calculated for C₁₁H₁₈N₇S⁺ 280.1339. Found 280.1343

3-(Imino(morpholino)methyl)-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4-amine (21m).

Morpholine (0.095 mL, 0.0011 mol, 1.1 equiv.) was added to a suspension of 4-amino-3-cyano-2-methylthio[1,2,4]triazolo[5,1-*c*][1,2,4]triazine **17b** (0.207 g, 0.001 mol) in MeCN (7 mL). The resulting mixture was refluxed for 4 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).



Green powder (252 mg, 86% yield). R_f (AcOEt) = 0.6. Mp = 295 °C. ^1H NMR (600 MHz, DMSO- d_6), δ , ppm. (J , Hz): 8.43 (br.s, 3NH, 3H); 3.71 (t, J = 4.5 Hz, 2CH₂, 4H); 3.56 (t, J = 4.5 Hz, 2CH₂, 4H); 2.61 (s, S-CH₃, 3H). ^{13}C NMR (150 MHz,


DMSO- d_6), δ , ppm.: 165.0, 160.6, 156.,7 141.7, 128.5, 65.6, 47.4, 13.4. IR, ν , cm⁻¹: 3288, 3042, 2976, 2911, 2866, 1683, 1662, 1621, 1594, 1516, 1484, 1446, 1423, 1407, 1373, 1337, 1303, 1290, 1269, 1243, 1204, 1170, 1144, 1119, 1069, 1028, 1013, 941, 874, 845, 798, 752, 739, 688, 671, 656, 635, 613, 577, 557, 526, 507. MS (EI, 70 eV), m/z : Calcd for: C₁₀H₁₄N₈OS, 294; found C₁₀H₁₄N₈OS, 294. Anal. Calcd. For C₁₀H₁₄N₈OS: C, 40.81; H, 4.79; N, 38.07; found: C, 40.88; H, 4.80; N, 38.03

General method for the synthesis of pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amines 23a-n.

Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.), appropriate amine (0.001 mol, 1 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 4-amino-3-cyano-7-methylsulfanyl[1,2,4]triazolo[5,1-*c*][1,2,4]triazine **18b** (0.207 g, 0.001 mol) in toluene (7 mL). The resulting mixture was refluxed for 8 hours, cooled to RT, filtered, and solids


were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).

2-(Methylthio)-*N*-propylpyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23a).




Yellow powder (259 mg, 94% yield). *R_f* (AcOEt) = 0.7. M.p. = 240 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.26 (s, NH, H); 8.62 (s, C8H, H); 3.66 (t, *J* = 7.3 Hz, NCH₂, 2H); 2.79 (s, S-CH₃, 3H); 1.71–1.81 (m, CH₂, 2H); 1.01 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.8, 162.8, 159.0, 157.7, 139.8, 123.3, 42.60, 21.7, 13.6, 11.2. IR, ν, cm⁻¹: 2358, 3207, 3154, 3128, 3113, 3001, 2952, 2929, 2895, 2863, 2838, 1610, 1572, 1533, 1464, 1439, 1413, 1392, 1364, 1328, 1308, 1275, 1186, 1128, 1098, 1087, 1073, 1013, 984, 969, 930, 913, 884, 864, 801, 785, 773, 749, 729, 705, 649, 588, 574, 552, 513. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₂N₈S, 276; found C₁₀H₁₂N₈S, 276. Anal. Calcd. For C₁₀H₁₂N₈S: C, 43.47; H, 4.38; N, 40.55; found: C, 43.44; H, 4.40; N, 40.59

***N*-Isopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23b).**



Yellow powder (248 mg, 90% yield). *R_f* (AcOEt) = 0.7. M.p. = 220 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.02 (s, NH, H); 8.61 (s, C8H, H); 4.73 (br.s, NCH, H); 2.79 (s, S-CH₃, 3H); 1.37 (d, *J* = 6.6 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.8, 162.8, 158.0, 157.7, 139.9, 123.2, 43.1, 21.5, 13.5. IR, ν, cm⁻¹: 3237, 3218, 3200, 3186, 3174, 3142, 3046, 2973, 2927, 1607, 11576, 1527, 1455, 1413, 1391, 1362, 1313, 1291, 1281, 1271, 1241, 1198, 1178, 1155, 1123, 1093, 1014, 976, 957, 930, 897, 878, 838, 801, 794, 965, 745, 734, 703, 667, 595, 580, 531, 524, 506. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₂N₈S, 276; found C₁₀H₁₂N₈S, 276. Anal. Calcd. For C₁₀H₁₂N₈S: C, 43.47; H, 4.38; N, 40.55; found: C, 43.55; H, 4.35; N, 40.55


***N*-Cyclopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23c).**



Yellow powder (155 mg, 93% yield). *R_f* (AcOEt) = 0.7. M.p. = 260 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.20 (s, NH, H); 8.68 (s, C8H, H); 3.43 (s, NCH, H); 2.79 (s, S-CH₃, 3H); 0.86–0.90 (m, CH₂, 2H), 0.94–0.98 (m, CH₂, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.9, 162.8, 160.1, 157.6, 139.7, 123.3, 25.0, 13.6, 5.9. IR, ν, cm⁻¹: 3295, 1600, 1575, 1533, 1509, 1478, 1396, 1366, 1332, 1310, 1277, 1201, 1185, 1131, 1106, 1059, 102, 989, 971, 934, 901, 888, 8435, 820, 802, 751, 737, 703, 692, 633, 611, 587, 577,


557, 543, 527, 508. MS (EI, 70 eV), m/z: Calcd for: C₁₀H₁₀N₈S, 274; found C₁₀H₁₀N₈S, 274. Anal. Calcd. For C₁₀H₁₀N₈S: C, 43.79; H, 3.67; N, 40.85; found: C, 43.88; H, 3.70; N, 40.88

***N*-Butyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23d).**




Yellow powder (278 mg, 96% yield). *R_f* (AcOEt) = 0.7. M.p. = 216 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.24 (s, NH, H); 8.62 (s, C8H, H); 3.69 (t, *J* = 7.3 Hz, NCH₂, 2H); 2.78 (s, S-CH₃, 3H); 1.69–1.74 (m, CH₂, 2H); 1.40–1.46 (m, CH₂, 2H); 0.98 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.9, 162.9, 159.0, 157.7, 139.9, 123.4, 40.6, 30.5, 19.6, 13.7, 13.6. IR, ν, cm⁻¹: 3202, 3164, 3142, 3083, 3062, 2967, 2928, 2868, 2854, 1513, 1572, 1535, 1468, 1438, 1411, 1389, 1361, 1330, 1307, 1273, 1248, 1183, 1099, 999, 982, 969, 886, 800, 783, 739, 705, 667, 622, 587, 555, 515. MS (EI, 70 eV), m/z: Calcd for: C₁₁H₁₄N₈S, 290; found C₁₁H₁₄N₈S, 290. Anal. Calcd. For C₁₁H₁₄N₈S: C, 45.50; H, 4.86; N, 38.59; found: C, 45.60; H, 4.76; N, 38.63

***N*-Isobutyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23e).**




Yellow powder (281 mg, 97% yield). *R_f* (AcOEt) = 0.7. M.p. = 211 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.27 (s, NH, H); 8.60 (s, C8H, H); 3.53 (d, *J* = 7.2 Hz, NCH₂, 2H); 2.79 (s, S-CH₃, 3H); 2.12–2.18 (m, CH, H); 1.00 (d, *J* = 6.7 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 168.8, 162.7, 159.1, 157.7, 139.9, 123.4, 48.2, 27.7, 20.1, 13.6. IR, ν, cm⁻¹: 3228, 3159, 3143, 3082, 3036, 3007, 2955, 2867, 2794, 1988, 1606, 1572, 1532, 1470, 1440, 1413, 1392, 1380, 1361, 1328, 1309, 1277, 1187, 1173, 1130, 1098, 1066, 979, 919, 883, 820, 800, 787, 749, 728, 705, 677, 640, 621, 607, 587, 562, 532, 513. MS (EI, 70 eV), m/z: Calcd for: C₁₁H₁₄N₈S, 290; found C₁₁H₁₄N₈S, 290. Anal. Calcd. For C₁₁H₁₄N₈S: C, 45.50; H, 4.86; N, 38.59; found: C, 45.55; H, 4.86; N, 38.50

***N*-(*Tert*-butyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23f).**




Yellow powder (119 mg, 41% yield). *R_f* (AcOEt) = 0.7. M.p. = 118 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 8.99 (s, NH, H); 8.67 (s, C8H, H); 2.79 (s, S-CH₃, 3H); 1.65 (s, 3CH₃, 9H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 169.0, 162.0, 158.7, 157.7, 139.7, 123.3, 53.9, 28.3, 13.6. IR, ν, cm⁻¹: 3559, 3484, 3446, 4468, 3272, 3197, 3139, 3122, 3070, 2978, 2965, 2993, 2823, 2015, 1627, 1597, 1569, 1532, 1452, 1398, 1325, 1283, 1209, 1189, 1145, 1114, 1014, 988, 967, 929, 885, 8557, 805, 795, 774, 714, 627, 589, 567, 557, 522, 504. MS (EI, 70 eV), m/z: Calcd for: C₁₁H₁₄N₈S, 290; found C₁₁H₁₄N₈S, 290. Anal. Calcd. For C₁₁H₁₄N₈S: C, 45.50; H, 4.86; N, 38.59; found: C, 45.48; H, 4.83; N, 38.66

3-((2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)amino)propan-1-ol (23g).




Yellow powder (210 mg, 72% yield). R_f (AcOEt) = 0.7. M.p. = 211 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 10.13 (d, J = 6.4 Hz, NH, H); 8.65 (s, C8H, H); 3.77 (dt, J_1 = 7.6 Hz, J_2 = 6.4 Hz, NCH $_2$, 2H); 3.56 (t, J = 6.1 Hz, OCH $_2$, 2H); 2.78 (s, S-CH $_3$, 3H); 1.86–1.91 (m, CH $_2$, 2H). ^{13}C NMR (150 MHz, DMSO- d_6), δ , ppm.: 168.9, 162.9, 159.0, 157.7, 139.8, 123.4, 58.6, 38.7, 31.5, 13.6. IR, ν , cm^{-1} : 3214, 3125, 2938, 2882, 1610, 1572, 1536, 1468, 1440, 1414, 1392, 1365, 1328, 1308, 1276, 1184, 1113, 1095, 1076, 1030, 1018, 969, 919, 886, 851, 802, 786, 731, 707, 667, 648, 590, 556, 525, 505. MS (EI, 70 eV), m/z : Calcd for: C $_{10}$ H $_{12}$ N $_8$ OS, 292; found C $_{10}$ H $_{12}$ N $_8$ OS, 292. Anal. Calcd. For C $_{10}$ H $_{12}$ N $_8$ OS: C, 41.09; H, 4.14; N, 38.33; found: C, 41.02; H, 4.13; N, 38.40

4-((2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)amino)butan-1-ol (23h).



The crude product was recrystallized from EtOH. Yellow powder (199 mg, 65% yield). R_f (AcOEt) = 0.7. M.p. = 203 °C. ^1H NMR (600 MHz, DMSO- d_6), δ , ppm. (J , Hz): 10.23 (br.s, NH, H); 8.69 (s, C8H, H); 4.45 (t, J = 4.8 Hz, OH, H); 3.67 (t, J = 6.6 Hz, NHCH $_2$, 2H); 3.44 (dt, J_1 = 6.6 Hz, J_2 = 4.8 Hz OCH $_2$, 2H); 2.76 (s, S-CH $_3$, 3H); 1.70–1.75 (m, CH $_2$, 2H); 1.49–1.54 (m, CH $_2$, 2H). ^{13}C NMR (150 MHz, DMSO- d_6), δ , ppm.: 168.9, 162.9, 159.0, 157.8, 139.9, 123.4, 60.4, 40.9, 29.8, 25.3, 13.6. IR, ν , cm^{-1} : 4308, 3348, 3271, 3168, 2960, 2942, 2907, 2862, 2829, 1675, 1622, 1575, 1532, 1501, 1470, 1449, 1416, 1388, 1369, 1324, 1308, 1275, 1197, 1184, 1173, 1136, 1116, 1091, 1073, 1055, 988, 973, 943, 903, 873, 836, 819, 804, 766, 729, 705, 691, 663, 646, 626, 612, 587, 558, 536, 512. MS (EI, 70 eV), m/z : Calcd for: C $_{11}$ H $_{14}$ N $_8$ OS, 306; found C $_{11}$ H $_{14}$ N $_8$ OS, 306. Anal. Calcd. For C $_{11}$ H $_{14}$ N $_8$ OS: C, 43.13; H, 4.61; N, 36.58; found: C, 43.02; H, 4.66; N, 36.49


2-(Methylthio)-*N*-(*p*-tolyl)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23i).



Orange powder (301mg, 93% yield). R_f (AcOEt) = 0.7. M.p. = 279 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 11.67 (s, NH, H); 8.75 (s, C8H, H); 7.83 (d, J = 8.0 Hz, 2CH, 2H); 7.23 (d, J = 8.0 Hz, 2CH, 2H); 2.80 (s, S-CH $_3$, 3H); 2.37 (s, CH $_3$, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 169.1, 162.5, 157.6, 157.32, 157.28, 139.8, 134.73, 134.65, 128.9, 123.3, 20.4, 13.5. IR, ν , cm^{-1} : 3280, 3262, 1618, 1583, 1565, 15344, 1510, 1425, 1407, 1386, 1358, 1326, 1282, 1214, 1184, 1112, 1018, 990, 981, 940, 906, 817, 801, 773, 736, 703, 663, 638, 582,


558, 529, 517, 507, 501. MS (EI, 70 eV), *m/z*: Calcd for: C₁₄H₁₂N₈S, 324; found C₁₄H₁₂N₈S, 324. Anal. Calcd. For C₁₄H₁₂N₈S: C, 51.84; H, 3.73; N, 34.55; found: C, 51.88; H, 3.60; N, 34.69

***N*-(4-Chlorophenyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23j).**




Yellow powder (169 mg, 49% yield). *R_f* (AcOEt) = 0.7. M.p. = 300 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 11.84 (s, NH, H); 8.81 (s, C8H, H); 8.06 (d, *J* = 8.8 Hz, 2CH, 2H); 7.42 (d, *J* = 8.8 Hz, 2CH, 2H); 2.82 (s, S-CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 169.2, 162.4, 157.5, 157.4, 139.8, 136.2, 129.2, 128.4, 124.8, 123.1, 13.5. IR, ν, cm⁻¹: 3237, 3079, 2985, 2350, 2242, 1899, 1730, 1650, 1608, 1575, 1558, 1535, 1509, 1485, 1426, 1401, 1385, 1323, 1279, 1212, 1184, 1143, 1112, 1089, 1008, 985, 962, 908, 829, 800, 731, 712, 701, 671, 653, 585, 579, 554, 523, 507. MS (EI, 70 eV), *m/z*: Calcd for: C₁₃H₉ClN₈SCl, 344; found C₁₃H₉ClN₈S, 344. Anal. Calcd. For C₁₃H₉ClN₈S: C, 45.29; H, 2.63; N, 32.50; found: C, 45.39; H, 2.40; N, 32.56

***N*-(4-Chlorophenethyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23k).**



The crude product was recrystallized from EtOH. Yellow powder (223 mg, 60% yield). *R_f* (AcOEt) = 0.7. M.p. = 284 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.26 (t, *J* = 6.0 Hz, NH, H); 8.70 (s, C8H, H); 7.30–7.34 (m, 4CH, 4H); 3.89 (dt, *J₁* = 7.2 Hz, *J₂* = 6.0 Hz, NCH₂, 2H); 3.02 (t, *J* = 7.2 Hz, CH₂, 2H); 2.76 (s, S-CH₃, 3H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ, ppm.: 168.9, 162.9, 159.1, 157.8, 139.9, 137.9, 130.9, 130.7, 128.3, 123.3, 42.1, 33.5, 13.6. IR, ν, cm⁻¹: 3366, 1613, 1570, 1537, 1515, 1491, 1470, 1454, 1432, 1412, 1386, 1365, 1356, 1340, 1326, 1274, 1174, 1143, 1109, 1089, 1068, 1027, 1011, 975, 887, 847, 845, 815, 801, 718, 705, 629, 586, 551, 524. MS (EI, 70 eV), *m/z*: Calcd for: C₁₅H₁₃ClN₈S, 372; found C₁₅H₁₃ClN₈S, 372. Anal. Calcd. For C₁₅H₁₃ClN₈S: C, 48.32; H, 3.51; N, 30.05; found: C, 48.25; H, 3.41; N, 29.89


4-(2-((2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)amino)ethyl)phenol (23l).



The crude product was recrystallized from EtOH. Yellow powder (160 mg, 45% yield). *R_f* (AcOEt) = 0.7. M.p. = 280 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 10.23 (t, *J* = 6.0 Hz, NH, H); 9.20 (s, OH, H); 8.70 (s, CH,


H); 7.06 (d, $J = 8.4$ Hz, 2CH, 2H); 6.69 (d, $J = 8.4$ Hz, 2CH, 2H); 3.83 (dt, $J_1 = 7.8$ Hz, $J_2 = 6.0$ Hz, CH₂, 2H); 2.90 (t, $J = 7.8$ Hz, CH₂, 2H); 2.75 (s, S-CH₃, 3H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ , ppm.: 168.9, 162.9, 159.0, 157.8, 155.8, 139.9, 129.6, 128.8, 123.4, 115.2, 42.7, 33.5, 13.6. IR, ν , cm⁻¹: 3250, 2149 3017, 2936, 2860, 1714, 1611, 1578, 1537, 1513, 1453, 1411, 1390, 1363, 1328, 1311, 1276, 1183, 1171, 1146, 1111, 1100, 1074, 1023, 987, 970, 890, 851, 828, 802, 725, 705, 677, 639, 588, 564, 550, 514. MS (EI, 70 eV), m/z : Calcd for: C₁₅H₁₄N₈OS, 354; found C₁₅H₁₄N₈OS, 354. Anal. Calcd. For C₁₅H₁₄N₈OS: C, 50.84; H, 3.98; N, 31.62; found: C, 50.86; H, 4.03; N, 31.59

4-(2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)morpholine (23m).



The crude product was recrystallized from EtOH. Orange powder (283 mg, 93% yield). R_f (AcOEt) = 0.65. M.p. = 221 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ , ppm. (J , Hz): 8.71 (s, CH, H); 4.87 (br.s, CH₂, 2H); 4.27 (br.s, CH₂, 2H); 3.85 (t, $J = 4.9$ Hz, 2CH₂, 4H); 2.65 (s, S-CH₃, 3H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ , ppm.: 166.1, 160.5, 157.2, 156.2, 142.1, 125.2, 66.3, 50.8, 46.7, 14.8. IR, ν , cm⁻¹: 2967, 2938, 2908, 2860, 1746, 1721, 1648, 1582, 1538, 1473, 1434, 1402, 1366, 1339, 1291, 1268, 1241, 1180, 1135, 1116, 1100, 1059, 1013, 983, 926, 903, 858, 813, 800, 751, 729, 690, 670, 648, 635, 600, 587, 541, 524. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₂N₈OS, 304; found C₁₁H₁₂N₈OS, 304. Anal. Calcd. For C₁₁H₁₂N₈OS: C, 43.41; H, 3.97; N, 36.82; found: C, 43.33; H, 3.95; N, 36.80

2-(Methylthio)-6-(piperidin-1-yl)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazine (23n).




The crude product was recrystallized from *i*-PrOH. Orange powder (200 mg, 66% yield). R_f (AcOEt) = 0.6. M.p. = 206 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ , ppm. (J , Hz): 8.63 (s, CH, H); 4.75 (br.s, CH₂, 2H); 4.23 (br.s, CH₂, 2H); 2.75 (s, S-CH₃, 3H); 1.79 (br.s, 3CH₂, 6H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ , ppm.: 168.8, 160.5, 156.7, 156.3, 141.6, 125.6, 51.1, 48.0, 26.6, 26.1, 23.8, 13.6. IR, ν , cm⁻¹: 2940, 2929, 2887, 2860, 2842, 1582, 1549, 1520, 1447, 1404, 1377, 1358, 1342, 1330, 1305, 1281, 1266, 1236, 1173, 1161, 1088, 1064, 1037, 1017, 974, 956, 898, 848, 796, 772, 705, 669, 652, 633, 611, 585, 575, 557, 536, 512. MS (EI, 70 eV), m/z : Calcd for: C₁₂H₁₄N₈S, 302; found C₁₂H₁₄N₈S, 302. Anal. Calcd. For C₁₂H₁₄N₈S: C, 47.67; H, 4.67; N, 37.06; found: C, 47.51; H, 4.80; N, 36.95. HRMS (ESI, Q-TOF), m/z : [M+H]⁺ Calculated for C₁₂H₁₅N₈S⁺ 303.1135. Found 303.1137

General method for the synthesis of pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amines 24a-h, 24j, 24l

Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.), appropriate amine (0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 7-


amino-6-cyano-2-(methylthio)[1,2,4]triazolo[1,5-*a*]pyrimidine **18a** (0.206 g, 0.001 mol) in toluene (7 mL). The resulting mixture was heated in autoclave at 140 °C for 12 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).

2-(Methylthio)-*N*-propylpyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24a).




Pale yellow powder (165 mg, 66% yield). *R_f* (AcOEt) = 0.4. M.p. = 282-283 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.54 (s, C5H, H); 9.21 (s, NH, H); 8.69 (s, C8H, H); 3.56 (dt, *J*₁ = 7.4 Hz, *J*₂ = 6.5 Hz, NCH₂, 2H); 2.68 (s, S-CH₃, 3H); 1.63–1.72 (m, CH₂, 2H); 0.96 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.9, 159.3, 156.5, 152.8, 149.3, 98.4, 42.8, 21.7, 13.4, 11.4. IR, ν, cm⁻¹: 3265, 3251, 3178, 3164, 3109, 2956, 1900, 1593, 1568, 1514, 1452, 1436, 1405, 1385, 1344, 1326, 1285, 1245, 1170, 1110, 1074, 1011, 983, 970, 924, 910, 890, 848, 798, 777, 755, 738, 696, 665, 586, 548, 510. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₃N₇S, 275; found C₁₁H₁₃N₇S, 275. Anal. Calcd. For C₁₁H₁₃N₇S: C, 47.98; H, 4.76; N, 35.61; found: C, 48.05; H, 4.90; N, 35.44

***N*-Isopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24b).**



Pale yellow powder (148 mg, 54% yield). *R_f* (AcOEt) = 0.3. M.p. = 248-249 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.60 (s, C5H, H); 8.89 (d, *J* = 7.5 Hz, NH, H); 8.70 (s, C8H, H); 4.53–4.61 (m, NHCH, H); 2.68 (s, S-CH₃, 3H); 1.30 (d, *J* = 6.6 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.9, 158.5, 156.6, 153.0, 149.5, 98.3, 43.1, 21.8, 13.4. IR, ν, cm⁻¹: 3255, 2486, 2451, 2205, 2170, 2971, 2932, 2350, 1592, 1571, 1518, 1462, 1414, 1384, 1349, 1329, 1301, 1285, 1253, 1161, 1014, 983, 920, 896, 839, 800, 756, 693, 581, 546, 534, 512. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₃N₇S, 275; found C₁₁H₁₃N₇S, 275. Anal. Calcd. For C₁₁H₁₃N₇S: C, 47.98; H, 4.76; N, 35.61; found: C, 47.99; H, 4.71; N, 35.58


***N*-Cyclopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24c).**



Pale yellow powder (136 mg, 50% yield). *R_f* (AcOEt) = 0.2. M.p. = 255-258 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.50 (s, C5H, H); 9.15 (br.s, NH, H); 8.75 (s, C8H, H); 3.12–3.17 (m, NHCH, H); 2.68 (s, S-CH₃, 3H); 0.86–0.90 (m, CH₂, 2H); 0.70–0.74 (m, CH₂, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.9, 160.6, 156.5, 153.0, 149.2, 98.5, 24.7, 13.4, 6.1. IR, ν, cm⁻¹: 3441, 3409, 3377, 3278, 3163, 3012, 1595, 1572, 1519, 1506, 1455, 1409,


1353, 1332, 1284, 1251, 1127, 1025, 984, 961, 944, 928, 894, 831, 819, 799, 745, 704, 690, 623, 576, 552, 533, 516. MS (EI, 70 eV), m/z: Calcd for: C₁₁H₁₁N₇S, 273; found C₁₁H₁₁N₇S, 273. Anal. Calcd. For C₁₁H₁₁N₇S: C, 48.34; H, 4.06; N, 35.87; found: C, 48.45; H, 3.95; N, 35.84

***N*-Butyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24d).**




Pale yellow powder (209 mg, 72% yield). *R_f* (AcOEt) = 0.6. M.p. = 257-258 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.53 (s, C5H, H); 9.19 (s, NH, H); 8.69 (s, C8H, H); 3.57–3.61 (m, NCH₂, 2H); 2.68 (s, S-CH₃, 3H); 1.61–1.66 (m, CH₂, 2H); 1.37–1.42 (m, CH₂, 2H); 0.93 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.9, 159.3, 156.6, 152.8, 149.4, 98.4, 40.7, 30.5, 19.6, 13.7, 13.4. IR, ν, cm⁻¹: 3280, 3269, 3198, 3169, 3139, 3110, 2958, 2933, 2871, 2859, 2342, 1595, 1571, 1523, 1451, 1406, 1387, 1375, 1357, 1343, 1320, 1285, 1247, 1169, 1113, 1072, 1054, 1002, 972, 920, 891, 799, 778, 756, 743, 729, 707, 691, 656, 584, 557, 546, 527, 511. MS (EI, 70 eV), m/z: Calcd for: C₁₂H₁₅N₇S, 289; found C₁₂H₁₅N₇S, 289. Anal. Calcd. For C₁₂H₁₅N₇S: C, 49.81; H, 5.23; N, 33.88; found: C, 49.81; H, 5.24; N, 33.75.

***N*-Isobutyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24e).**



Pale yellow powder (196 mg, 68% yield). *R_f* (AcOEt) = 0.5. M.p. = 277-278 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.57 (s, C5H, H); 9.21 (s, NH, H); 8.67 (s, C8H, H); 3.42 (d, *J* = 7.0 Hz, NCH₂, 2H); 2.68 (s, S-CH₃, 3H); 1.97–2.07 (m, CH, H); 0.96 (d, *J* = 6.7 Hz, 2CH₃, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.9, 159.6, 156.6, 152.9, 149.4, 98.5, 48.4, 27.6, 20.2, 13.4. IR, ν, cm⁻¹: 3284, 3173, 2958, 2928, 2869, 1592, 1569, 1521, 1451, 1436, 1404, 1385, 1354, 1343, 1323, 1285, 1246, 1171, 1112, 1065, 971, 902, 889, 876, 816, 799, 756, 738, 705, 647, 585, 560, 545, 516. MS (EI, 70 eV), m/z: Calcd for: C₁₂H₁₅N₇S, 289; found C₁₂H₁₅N₇S, 289. Anal. Calcd. For C₁₂H₁₅N₇S: C, 49.81; H, 5.23; N, 33.88; found: C, 49.90; H, 5.09; N, 33.71


***N*-(*Tert*-butyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24f).**



The crude product was recrystallized from *iso*-propanol. Pale yellow crystals (58 mg, 20% yield). *R_f* (AcOEt) = 0.5. M.p. = 255-256 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.69 (s, C5H, H); 8.65 (s, C8H, H); 8.26 (s, NH, H); 2.71 (s, S-CH₃, 3H); 1.58 (s, 3CH₃, 9H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 161.0, 159.3, 156.5, 153.7, 149.5, 98.9, 53.8, 28.4, 13.4. IR, ν, cm⁻¹: 3327, 3290, 3083, 2962, 2931, 2221, 1655, 1584, 1568, 1517, 1476, 1458, 1434, 1409, 1349, 1288, 1243, 1200, 1136, 1114, 1011, 988, 967, 948, 899, 803, 768, 708, 675, 641, 579, 551, 534. MS (EI, 70 eV), m/z: Calcd for: C₁₂H₁₅N₇S,

289; found C₁₂H₁₅N₇S, 289. Anal. Calcd. For C₁₂H₁₅N₇S: C, 49.81; H, 5.23; N, 33.88; found: C, 49.91; H, 5.25; N, 33.88


3-((2-(Methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-yl)amino)propan-1-ol (24g).



The crude product was recrystallized from EtOH. Pale yellow powder (125 mg, 43% yield). *R*_f (AcOEt) = 0.4. M.p. = 246-247 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.52 (s, C5H, H); 9.20 (t, *J* = 6.0

Hz, NH, H); 8.68 (s, C8H, H); 4.57 (t, *J* = 5.4 Hz, OH, H); 3.65 (dt, *J*₁ = 7.8 Hz, *J*₂ = 6.0 Hz, NCH₂, 2H); 3.52 (dt, *J*₁ = 6.6 Hz, *J*₂ = 5.4 Hz, OCH₂, 2H); 2.68 (s, S-CH₃, 3H); 1.79–1.84 (m, CH₂, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 162.0, 159.4, 156.6, 152.9, 149.4, 98.6, 58.4, 38.5, 31.7, 13.4. IR, ν, cm⁻¹: 3442, 3369, 3336, 3238, 3195, 3164, 3116, 2990, 2951, 2915, 2870, 2772, 2744, 2675, 2652, 1651, 1594, 1570, 1518, 1455, 1405, 1341, 1285, 1252, 1191, 1154, 1122, 1094, 1070, 1020, 969, 944, 894, 854, 800, 759, 726, 702, 624, 575, 559, 519. MS (EI, 70 eV), *m/z*: Calcd for: C₁₁H₁₃N₇OS, 291; found C₁₁H₁₃N₇OS, 291. Anal. Calcd. For C₁₁H₁₃N₇OS: C, 45.35; H, 4.50; N, 33.66; found: C, 45.47; H, 4.36; N, 33.80


4-((2-(Methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-yl)amino)butan-1-ol (24h).



The crude product was recrystallized from EtOH. Pale yellow powder (195 mg, 64% yield). *R*_f (AcOEt) = 0.1. M.p. = 201-202 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.52 (s, C5H,

H); 9.21 (t, *J* = 6.0 Hz, NH, H); 8.68 (s, C8H, H); 4.46 (t, *J* = 4.8 Hz, OH, H); 3.59 (dt, *J*₁ = 7.2 Hz, *J*₂ = 6.4 Hz, NCH₂, 2H), 3.45 (dt, *J*₁ = 7.6 Hz, *J*₂ = 6.0 Hz, OCH₂, 2H); 2.68 (s, S-CH₃, 3H); 1.68–1.72 (m, CH₂, 2H); 1.51–1.56 (m, CH₂, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆), δ, ppm.: 166.6, 162.0, 159.4, 156.6, 152.9, 149.4, 98.5, 60.4, 41.0, 29.9, 25.2, 13.4. IR, ν, cm⁻¹: 3402, 3312, 3229, 3132, 3104, 3009, 2943, 2883, 1584, 1467, 1516, 1480, 1452, 1410, 1372, 1349, 1333, 1280, 1249, 1227, 1160, 1121, 1090, 1062, 1027, 999, 985, 962, 939, 903, 879, 826, 801, 756, 722, 701, 668, 632, 577, 559, 522, 511. MS (EI, 70 eV), *m/z*: Calcd for: C₁₂H₁₅N₇OS, 305; found C₁₂H₁₅N₇OS, 305. Anal. Calcd. For C₁₂H₁₅N₇OS: C, 47.20; H, 4.95; N, 32.11; found: C, 47.11; H, 5.06; N, 32.00. HRMS (ESI, Q-TOF), *m/z*: [M+H]⁺ Calculated for C₁₂H₁₆N₇OS⁺ 306.1132. Found 306.1132


***N*-(4-Chlorophenethyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24k).**



Pale yellow powder (274 mg, 74% yield). R_f (AcOEt) = 0.3. M.p. = 283-294 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.49 (s, C5H, H); 9.26 (t, J = 5.7 Hz, NH, H); 8.65 (s, C8H, H); 7.29 (s, 4CH, 4H); 3.83 (dt, J_1 = 6.8 Hz, J_2 = 5.7

Hz, NCH₂, 2H); 2.98 (t, J = 7.4 Hz, CH₂, 2H); 2.71 (s, S-CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 166.6, 161.9, 159.3, 156.6, 155.8, 152.7, 149.3, 129.6, 128.9, 115.2, 98.5, 42.9, 33.6, 13.4. IR, ν , cm⁻¹: 3314, 3293, 3269, 3253, 3196, 3106, 3019, 2940, 2906, 2871, 1901, 1589, 1572, 1522, 1488, 1454, 1436, 1404, 1388, 1355, 1322, 1285, 1248, 1202, 1139, 1116, 1092, 1063, 1015, 984, 971, 894, 841, 812, 799, 777, 755, 733, 717, 706, 662, 598, 553, 518. MS (EI, 70 eV), m/z : Calcd for: C₁₆H₁₄Cl³⁵N₇S, 371; found C₁₆H₁₄Cl³⁵N₇S, 371. Anal. Calcd. For C₁₆H₁₄ClN₇S: C, 51.68; H, 3.79; N, 26.37; found: C, 51.77; H, 3.74; N, 26.19

4-(2-((2-(Methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-yl)amino)ethyl)phenol (24l).




Orange powder (109 mg, 31% yield). R_f (AcOEt) = 0.6. M.p. = 229-230 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.50 (s, C5H, H); 9.25 (t, J = 6.4 Hz, NH, H); 8.98 (s,

OH, H); 8.65 (s, C8H, H); 7.03 (d, J = 8.4 Hz, 2CH, 2H); 6.66 (d, J = 8.4 Hz, 2CH, 2H); 3.86 (dt, J_1 = 8.0 Hz, J_2 = 6.4 Hz, NCH₂, 2H); 2.86 (t, J = 8.0 Hz, CH₂, 2H); 2.71 (s, S-CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 166.5, 161.5, 159.2, 156.3, 152.4, 149.1, 137.7, 130.7, 130.2, 127.9, 98.2, 41.9, 33.4, 13.1. IR, ν , cm⁻¹: 1570, 1513, 1444, 1407, 1335, 1278, 1259, 1225, 1147, 1114, 1075, 978, 898, 854, 828, 801, 726, 704, 580, 553, 507. MS (EI, 70 eV), m/z : Calcd for: C₁₆H₁₅N₇OS, 353; found C₁₆H₁₅N₇OS, 353. Anal. Calcd. For C₁₆H₁₅N₇OS: C, 54.38; H, 4.28; N, 27.74; found: C, 54.44; H, 4.39; N, 27.71

General method for the synthesis of *N'*-([1,2,4]triazoloaziny)-*N,N*-dimethylformimide 27a, 27b, 28a, 28b.


DMF-DMA (0.200 mL, 0.0015 mol, 1.5 equiv.) was added to a suspension of appropriate [1,2,4]triazoloazine **17a/17b/18a/18b** (0.001 mol) in 1,4-dioxane (7 mL). The resulting mixture was refluxed for 3 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

Ethyl 4-(((dimethylamino)methylene)amino)-7-(methylthio)-[1,2,4]triazolo[5,1-c][1,2,4]triazine-3-carboxylate (27a).




Light brown powder (269 mg, 87% yield). R_f (AcOEt) = 0.5. M.p. = 167 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.10 (s, CH, H); 4.38 (q, J = 7.1 Hz, CH₂, 2H); 3.35 (s, CH₃, 3H); 3.24 (s, CH₃, 3H); 2.71 (s, S-CH₃, 3H); 1.39 (t, J = 7.1 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 169.1, 164.0, 160.2, 157.6, 141.0, 132.3, 61.3, 41.4, 34.9, 14.1, 13.5. IR, ν , cm⁻¹: 2994, 2978, 2956, 2929, 1703, 1642, 1621, 1548, 1514, 1369, 1437, 1400, 1364, 1345, 1326, 1314, 1294, 1201, 1143, 1102, 1056, 1008, 968, 862, 847, 792, 755, 723, 706, 680, 637, 600, 589, 566, 538, 519, 503. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₅N₇O₂S, 309; found C₁₁H₁₅N₇O₂S, 309. Anal. Calcd. For C₁₁H₁₅N₇O₂S: C, 42.71; H, 4.89; N, 31.69; found: C, 42.75; H, 4.89; N, 31.78

***N'*-(3-Cyano-7-(methylthio)-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-yl)-*N,N*-dimethylformimide (27b).**



Green powder (231 mg, 88% yield). R_f (AcOEt) = 0.6. M.p. = 222 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.59 (s, CH, H); 3.44 (s, CH₃, 3H); 3.34 (s, CH₃, 3H); 2.74 (s, S-CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 169.6, 161.1, 157.4, 142.9, 119.2, 115.6, 42.2, 35.3, 13.5. IR, ν , cm⁻¹: 3202, 3164, 3142, 3083, 3062, 2967, 2928, 2868, 2854, 1513, 1572, 1535, 1468, 1438, 1411, 1389, 1361, 1330, 1307, 1273, 1248, 1183, 1099, 999, 982, 969, 886, 800, 783, 739, 705, 667, 622, 587, 555, 515. MS (EI, 70 eV), m/z : Calcd for: C₉H₁₀N₈S, 262; found C₉H₁₀N₈S, 262. Anal. Calcd. For C₉H₁₀N₈S: C, 41.21; H, 3.84; N, 42.72; found: C, 41.17; H, 3.88; N, 42.70


Ethyl 7-(((dimethylamino)methylene)amino)-2-(methylthio)-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate (28a).



Pale yellow powder (293 mg, 95% yield). R_f (AcOEt) = 0.45. M.p. = 135 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 8.83 (s, CH, H); 8.45 (s, C5H, H); 4.24 (q, J = 7.1 Hz, CH₂, 2H); 3.23 (s, CH₃, 3H); 3.15 (s, CH₃, 3H); 2.62 (s, S-CH₃, 3H); 1.28 (t, J = 7.1 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 166.8, 164.5, 159.1, 157.4, 156.4, 152.2, 102.3, 60.6, 40.6, 34.6, 14.0, 13.3. IR, ν , cm⁻¹: 2994, 2976, 2929, 2900, 2873, 1718, 1704, 1632, 1571, 15337, 1521, 1472, 1416, 1393, 1368, 1333, 1315, 1110, 1092, 1025, 991, 981, 955, 876, 864, 782, 711, 695, 682, 652, 624, 612, 592, 574, 539, 522. MS (EI, 70 eV), m/z : Calcd for: C₁₂H₁₆N₆O₂S, 308; found


C₁₂H₁₆N₆O₂S, 308. Anal. Calcd. For C₁₂H₁₆N₆O₂S: C, 46.74; H, 5.23; N, 27.25; found: C, 46.85; H, 5.11; N, 27.13

***N'*-(6-Cyano-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidin-7-yl)-*N,N*-dimethylformimidamide (28b).**



Pale yellow powder (217 mg, 83% yield). *R_f* (AcOEt) = 0.55. M.p. = 241 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.39 (s, CH, H); 8.66 (s, C5H, H); 3.33 (s, CH₃, 3H); 3.23 (s, CH₃, 3H); 2.65 (s, S-CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 167.4, 159.9, 157.5, 156.5, 151.1, 115.8, 87.3, 41.4, 34.6, 13.1. IR, ν, cm⁻¹: 2218, 1625, 1576, 1537, 1503, 1470, 1435, 1391, 1364, 1335, 1283, 1252, 1215, 1130, 1108, 985, 958, 916, 859, 809, 762, 736, 712, 684, 605, 554, 521. MS (EI, 70 eV), *m/z*: Calcd for: C₁₀H₁₁N₇S, 261; found C₁₀H₁₁N₇S, 261. Anal. Calcd. For C₁₀H₁₁N₇S: C, 45.96; H, 4.24; N, 37.52; found: C, 46.03; H, 4.23; N, 37.66

2-(Methylthio)-7-((morpholinomethylene)amino)-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carbonitrile (29).




Morpholine (0.130 mL, 0.0015 mol, 1.5 equiv.) was added to a suspension of *N'*-(6-cyano-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidin-7-yl)-*N,N*-dimethylformimidamide **28b** (0.261 g, 0.001 mol) in MeCN (7 mL). The resulting mixture was refluxed for 7 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

White powder (203 mg, 67% yield). *R_f* (AcOEt) = 0.7. M.p. = 216 °C. ¹H NMR (600 MHz, DMSO-*d*₆), δ, ppm. (*J*, Hz): 9.53 (s, CH, H); 8.72 (s, C5H, H); 3.90 (t, *J* = 5.1 Hz, CH₂, 2H); 3.78 (t, *J* = 5.1 Hz, 3CH₂, 6H); 2.65 (s, S-CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ, ppm.: 167.7, 158.9, 157.7, 156.8, 151.3, 116.0, 87.7, 66.4, 65.4, 50.7, 43.6, 13.3. IR, ν, cm⁻¹: 3018, 3008, 2990, 2928, 2871, 2226, 1605, 1582, 1543, 1520, 1456, 1445, 1431, 1398, 1351, 1317, 1302, 1290, 1267, 1258, 1243, 1176, 1110, 1067, 1021, 992, 976, 969, 952, 931, 902, 861, 819, 791, 768, 738, 709, 688, 672, 638, 619, 594, 572, 550, 529, 518. MS (EI, 70 eV), *m/z*: Calcd for: C₁₂H₁₃N₇OS, 303; found C₁₂H₁₃N₇OS, 303. Anal. Calcd. For C₁₂H₁₃N₇OS: C, 47.51; H, 4.32; N, 32.32; found: C, 47.65; H, 4.25; N, 32.40

4-Amino-*N*-butyl-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazine-3-carboxamide (30d).


n-Butylamine (0.300 mL, 0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 2-methylthio-3-ethoxycarbonyl-4-amino[1,2,4]triazolo[5,1-*c*][1,2,4]triazine **17a** (0.001 mol) in toluene (7 mL). The resulting mixture was heated at 140 °C in autoclave for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).



White powder (225 mg, 80% yield). R_f (AcOEt) = 0.1. M.p. = 203 °C. ^1H NMR (600 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.96 (br.s, NH, H); 9.45 (br.s, NH₂, H); 8.82 (br.s, NH₂, H); 3.45 (t, J = 7.4 Hz, NCH₂, 2H); 2.63 (s, S-CH₃, 3H); 1.60–1.65 (m, CH₂, 2H); 1.35–1.41 (m, CH₂, 2H); 0.92 (t, J = 7.4 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 166.1, 159.6, 158.8, 149.6, 123.1, 41.2, 29.8, 19.4, 13.6, 13.4. IR, ν , cm⁻¹: 3390, 3200, 2986, 2932, 2851, 2719, 1700, 1640, 1546, 1465, 1441, 1409, 13390, 1372, 1347, 1325, 1295, 1269, 1241, 1178, 1164, 1083, 1003, 970, 913, 853, 788, 776, 758, 708, 687, 669, 643, 616, 576, 554. MS (EI, 70 eV), m/z : Calcd for: C₁₀H₁₅N₇OS, 281; found C₁₀H₁₅N₇OS, 281. Anal. Calcd. For C₁₀H₁₅N₇OS: C, 42.69; H, 5.37; N, 34.85; found: C, 42.77; H, 5.40; N, 34.69

General method for the synthesis of pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amines 36-39.


Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.), *n*-butylamine (0.300 mL, 0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of appropriate 7-amino-6-cyano[1,2,4]triazolo[1,5-*a*]pyrimidine **32-35** (0.001 mol) in toluene (7 mL). The resulting mixture was heated in autoclave at 140 °C for 12 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).



***N*-butylpyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (36).**


Yellow powder (192 mg, 79% yield). R_f (AcOEt) = 0.6. M.p. = 235 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.59 (s, C5H, H); 9.19 (s, NH, H); 8.71 (s, C2H, H); 8.65 (s, C8H, H); 3.58 (t, J = 7.1 Hz, NCH₂, 2H); 1.60–1.67 (m, CH₂, 2H); 1.34–1.43 (m, CH₂, 2H); 0.92 (t, J = 7.4 Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 161.9, 159.4, 155.9, 155.1, 153.0, 150.5, 98.7, 40.8, 30.5, 19.6, 13.7. IR, ν , cm⁻¹: 3308, 3258, 3174, 3162, 3103, 2955, 2936, 2872, 1603, 1592, 1574, 1525, 1515, 1457, 1442, 1420, 1496, 1356, 1315, 1260, 1249, 1229, 1183, 1171, 1115, 1099, 1067, 1006, 946, 926, 892, 801, 748, 726, 704, 685, 667, 650, 603, 576, 560, 542, 518, 507. MS (EI, 70 eV), m/z : Calcd for: C₁₁H₁₃N₇, 243; found C₁₁H₁₃N₇, 243. Anal. Calcd. For C₁₁H₁₃N₇: C, 54.31; H, 5.39; N, 40.30; found: C, 54.33; H, 5.45; N, 40.39

Ethyl 4-(butylamino)pyrazolo[1,5-*a*]pyrimido[5,4-*e*]pyrimidine-7-carboxylate (37).




White powder (165 mg, 77% yield). R_f (AcOEt) = 0.6. M.p. > 300 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.45 (s, C5H, H); 9.04 (br.s, NH, H); 8.70 (s, C2H, H); 8.55 (s, C8H, H); 4.32 (dt, $J_1 = 6.8$ Hz, $J_2 = 8.0$ Hz, NCH₂, 2H); 3.60 (q, $J = 7.2$ Hz, OCH₂, 2H); 1.64–1.68 (m, CH₂, 2H); 1.38–1.42 (m, CH₂, 2H); 1.34 (t, $J = 7.1$ Hz, CH₃, 3H); 0.94 (t, $J = 7.2$ Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 161.7, 161.3, 159.1, 150.1, 149.9, 147.8, 146.2, 104.5, 98.2, 59.5, 40.6, 30.4, 19.4, 14.1, 13.4. IR, ν , cm⁻¹: 3289, 3181, 3146, 3001, 2958, 2932, 2866, 1711, 1595, 1573, 1553, 1486, 1451, 1434, 1400, 1379, 1354, 1254, 1222, 1180, 1126, 1103, 1022, 985, 945, 917, 890, 835, 799, 772, 742, 703, 673, 633, 610, 549, 538, 508. MS (EI, 70 eV), m/z : Calcd for: C₁₅H₁₈N₆O₂, 314; found C₁₅H₁₈N₆O₂, 314. Anal. Calcd. For C₁₅H₁₈N₆O₂: C, 57.31; H, 5.77; N, 26.74; found: C, 57.40; H, 5.66; N, 26.89

3-Butyl-4-imino-3,4-dihydropyrazolo[1,5-*a*]pyrimido[5,4-*e*]pyrimidine-7-carbonitrile (38).



The crude product was recrystallized from EtOH. Yellow powder (200 mg, 75% yield). R_f (AcOEt) = 0.6. M.p. = 252 °C. ^1H NMR (600 MHz, DMSO- d_6), δ , ppm. (J , Hz): 9.48 (s, C5H, H); 9.23 (t, $J = 5.4$ Hz, NH, H); 8.78 (s, C2H, H); 8.72 (s, C8H, H); 3.58 (t, $J = 7.2$ Hz, NCH₂, 2H); 1.62–1.66 (m, CH₂, 2H); 1.36–1.43 (m, CH₂, 2H); 0.93 (t, $J = 7.2$ Hz, CH₃, 3H). ^{13}C NMR (150 MHz, DMSO- d_6), δ , ppm.: 162.2, 159.3, 151.2 (2C), 150.4, 146.8, 113.2, 99.0, 84.0, 40.8, 30.5, 19.6, 13.7. IR, ν , cm⁻¹: 3372, 3328, 3292, 2958, 2939, 2873, 2241, 1605, 1594, 1572, 1470, 1452, 1429, 1395, 1357, 1336, 1312, 1254, 1236, 1187, 1155, 1109, 1071, 1009, 992, 946, 917, 904, 889, 799, 738, 707, 683, 662, 637, 630, 600, 555, 539, 513. MS (EI, 70 eV), m/z : Calcd for: C₁₃H₁₃N₇, 267; found C₁₃H₁₃N₇, 267. Anal. Calcd. For C₁₃H₁₃N₇: C, 58.42; H, 4.90; N, 36.68; found: C, 58.51; H, 4.80; N, 36.66

***N*-Butyl-2-methyl-5-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (39).**




White powder (167 mg, 55% yield). R_f (AcOEt) = 0.5. M.p. = 223 °C. ^1H NMR (400 MHz, DMSO- d_6), δ , ppm. (J , Hz): 8.62 (s, C8H, H); 7.75 (br.s, NH, H); 3.64 (t, $J = 6.8$ Hz, NCH₂, 2H); 2.75 (s, S-CH₃, 3H); 2.45 (s, CH₃, 3H); 1.61–1.68 (m, CH₂, 2H); 1.37–1.46 (m, CH₂, 2H); 0.94 (t, $J = 7.2$ Hz, CH₃, 3H). ^{13}C NMR (100 MHz, DMSO- d_6), δ , ppm.: 164.5, 164.0, 160.1, 158.6, 154.2, 149.8, 97.4, 41.5, 30.3, 19.6, 14.7, 14.1, 13.7. IR, ν , cm⁻¹: 3385, 3005, 2957, 2925,

2891, 2870, 2834, 1592, 1556, 1498, 1454, 1402, 1369, 1458, 1328, 1267, 1249, 1233, 1181, 1113, 1073, 1037, 1016, 994, 978, 963, 892, 848, 803, 765, 752, 736, 715, 691, 670, 660, 650, 631, 616, 602, 577, 538. MS (EI, 70 eV), m/z : Calcd for: $C_{13}H_{17}N_7S$, 303; found $C_{13}H_{17}N_7S$, 303. Anal. Calcd. For $C_{13}H_{17}N_7S$: C, 51.47; H, 5.65; N, 32.32; found: C, 51.56; H, 5.72; N, 32.27

***N*-Butyl-8-methyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (40).**

Triethylorthoacetate (0.549 mL, 0.003 mol, 3 equiv.), *n*-butylamine (0.300 mL, 0.003 mol, 3 equiv.) and AcOH (0.172 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 4-amino-3-cyano-7-methylsulfanyl[1,2,4]triazolo[5,1-*c*][1,2,4]triazine **18b** (0.207 g, 0.001 mol) in toluene (7 mL). The resulting mixture was heated in autoclave at 140 °C for 12 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of product could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was

treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).



Brown powder (67 mg, 22% yield). R_f (AcOEt) = 0.65.

M.p. = 259 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ , ppm. (*J*, Hz): 10.04 (s, NH, H); 3.68 (br.s, NCH₂, 2H); 2.78 (s, S-CH₃, 3H); 2.62 (s, CH₃, 3H); 1.67–1.74 (m, CH₂, 2H);

1.38–1.48 (m, CH₂, 2H); 0.99 (t, *J* = 7.4 Hz, CH₃, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆), δ , ppm.: 173.4, 168.7, 158.7, 157.7, 139.9, 122.1, 40.4, 30.5, 27.2, 19.5, 13.6, 13.6. IR, ν , cm⁻¹: 3269, 3252, 3158, 2958, 2930, 2872, 2819, 1688, 1614, 1580, 1530, 1484, 1468, 1441, 1375, 1338, 1294, 1276, 1211, 1184, 1140, 1113, 1089, 1030, 990, 936, 921, 859, 839, 815, 800, 766, 741, 718, 703, 669, 642, 626, 570, 541, 524, 514. MS (EI, 70 eV), m/z : Calcd for: $C_{12}H_{16}N_8S$, 304; found $C_{12}H_{16}N_8S$, 304. Anal. Calcd. For $C_{12}H_{16}N_8S$: C, 47.35; H, 5.30; N, 36.81; found: C, 47.26; H, 5.34; N, 36.96

Alternative method for the synthesis of *N*-butyl-2-(methylthio)pyrimido[1,2,4]triazoloazin-6-amines **23d, **24d** from aminocyano[1,2,4]triazoloazines **17b**, **18b**.**

Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.) and *n*-butylamine (0.300 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of appropriate aminocyano[1,2,4]triazoloazine **17b**, **18b** (0.001 mol) in toluene (7 mL). The resulting mixture was heated at 140 °C in autoclave for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of products could be obtained from the mother liquor. The mother liquor was concentrated at reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).

Alternative method for the synthesis of *N*-butyl-2-(methylthio)pyrimido[1,2,4]triazolo-azin-6-amines 23d, 24d from *N'*-(cyano-(methylthio)-[1,2,4]triazoloazinyl)-*N,N*-dimethylformimidamides 27b, 28b.

n-Butylamine (0.300 mL, 0.003 mol, 3 equiv.) was added to a suspension of appropriate *N'*-(cyano-(methylthio)-[1,2,4]triazoloazinyl)-*N,N*-dimethylformimidamide **27b, 28b** (0.001 mol) in MeCN (7 mL). The resulting mixture was refluxed for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

Alternative method for the synthesis of *N*-butyl-2-(methylthio)pyrimido[1,2,4]triazoloazin-6-amines 23d, 24d from amino-*N*-butyl-(methylthio)-[1,2,4]triazoloazinecarboximidamides 21d, 22d

A mixture of appropriate amino-*N*-butyl-(methylthio)-[1,2,4]triazoloazinecarboximidamide **21d, 22d** (0.001 mol) and triethylorthoformate (5 mL) was heated at reflux for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

Alternative method for the synthesis of 7-butyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7H)-one 20d from 2-methylthio-6-ethoxycarbonyl-7-amino-[1,2,4]triazolo[1,5-*a*]pyrimidine 18a.

Triethylorthoformate (0.498 mL, 0.003 mol, 3 equiv.) and *n*-butylamine (0.300 mL, 0.003 mol, 3 equiv.) were added consequently to a suspension of 2-methylthio-6-ethoxycarbonyl-7-amino-[1,2,4]triazolo[1,5-*a*]pyrimidine **18a** (0.253 g, 0.001 mol) in toluene (7 mL). The resulting mixture was heated at 140 °C in autoclave for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

Alternative method for the synthesis of 4-(2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)morpholine 23m from *N'*-(6-cyano-2-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)-*N,N*-dimethylformimidamide 27b.

Morpholine (0.260 mL, 0.003 mol, 3 equiv.) was added to a suspension of *N'*-(6-cyano-2-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)-*N,N*-dimethylformimidamide **27b** (0.001 mol) in MeCN (7 mL). The resulting mixture was refluxed for 8 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL).

Alternative method for the synthesis of 4-(2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)morpholine 23m from 3-(imino(morpholino)methyl)-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4-amine 21m.

A mixture of 3-(imino(morpholino)methyl)-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4-amine **21m** (0.001 mol), triethylorthoformate (5 mL), and AcOH (5 mL) was heated at reflux for 6 hours, cooled to RT, filtered, and solids were washed with Et₂O (5 mL). Another crop of products could be obtained from the mother liquor. The mother liquor was concentrated at

reduced pressure, the residue was treated with Et₂O (10 mL), filtered, and solids were washed with Et₂O (5 mL).

Table 1. X-ray data for compound **23d**.

Parameter	Compound 23d
Empirical formula	C ₁₁ H ₁₄ N ₈ S
Formula weight	290.36
T/K	295(2)
Crystal system	orthorhombic
Space group	Pbca
a/Å	13.0522(13)
b/Å	7.5876(12)
c/Å	28.440(4)
α/°	90
β/°	90
γ/°	90
V/Å ³	2816.5(6)
Z	8
ρ _{calc} /g/cm ³	1.370
μ/mm ⁻¹	0.234
F(000)	1216.0
Crystal size/mm ³	0.48 × 0.17 × 0.06
Radiation	Mo Kα (λ = 0.71073)
Index ranges	-9 ≤ h ≤ 17, -10 ≤ k ≤ 10, -39 ≤ l ≤ 18
2θ range for data collection/°	5.72 to 61
Reflections collected	11951
Independent reflections	3957 [R _{int} = 0.0785, R _{sigma} = 0.0890]
Data/restraints/parameters	3957/0/184
Goodness-of-fit on F ²	0.999
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0828, wR ₂ = 0.2002
Final R indexes [all data]	R ₁ = 0.1891, wR ₂ = 0.2670
Largest diff. peak/hole / e Å ⁻³	0.28/-0.29

Cell Culture

Experiments were carried out on cultured human glioblastoma cells (A172, ATCC CRL 1620), human lung carcinoma (A549, ATCC CCL 185), human liver carcinoma (HepG2, ATCC HB 8065), human embryo kidney cells (HEK-293, ATCC CRL 1573) obtained from a shared research facility, the “Vertebrate Cell Culture Collection” (Institute of Cytology RAS, St. Petersburg, Russia). The cells were cultured using DMEM/F-12 medium containing 10% fetal bovine serum (FBS) at 37°C, 5% CO₂ and 98% humidity. Subculturing using 0.25% trypsin solution was performed when the culture reached ≥ 90% confluency. DMEM/F-12, FBS and Trypsin were purchased from Biolot Ltd., St. Petersburg, Russia.

In vitro cytotoxicity assay

The compounds were dissolved in DMSO. The solutions were diluted with DMEM/F-12 culture medium with 10 % FBS to the studied concentrations: 8–1024; 2–256; 1–128 μ M. In all cases, the concentration of DMSO in the final solution did not exceed 1%. Cisplatin (1134357, U. S. Pharmacopeia, USA) was used as a comparison compound.


Cells were seeded in 96-well plates at a concentration of 4×10^3 cells per well. After 24 h, test compounds were added to the wells in a given concentration range. Then, the cells were incubated for 72 h, after which a solution of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide) (Dia-m, Russia) was added to the cultures at 20 μ L (5 mg/mL) per well. After 2 h, the medium was removed from the wells and 200 μ L of a mixture of DMSO and propanol-2, 1:1, was added. Optical density was measured on a plate spectrophotometer (Victor Nivo™, PerkinElmer, USA) at a wavelength of 570 nm.

Statistical Analysis

Statistical data processing was carried out in the RStudio program (Version 2023.09.1© 2009-2023 RStudio, PBC) using the R package (version 4.3.2). The cytotoxicity index (IC₅₀) was calculated by plotting dose–response curves using the «drc» package.¹


1. C. Ritz, F. Baty, J.C. Streibig, D. Gerhard. Dose-Response Analysis Using R. PLoS One. 10 (2015). <https://doi.org/10.1371/journal.pone.0146021>.

^1H NMR, 400 MHz, DMSO- d_6 (blank solvent for spectra recorded at 400 MHz)




7-Propyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19a)

2437 Be 619-2.1.fid
Rusinov Be 619/2



¹H, 400 MHz, DMSO-D₆



2643.13.fid
Rusinov Be 619-2

—170.51

157.82

157.78

157.28

—140.21


—129.15

—48.84


~21.64

~13.63


~10.64



^{13}C , 100 MHz, DMSO- D_6



S31




Line#:1 R.Time:2.370(Scan#:909)

MassPeaks:142


RawMode:Single 2.370(909) BasePeak:277(2554332)

Фон.реж.:1.138(416) Group 1 - Event 1



7-Isopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19b)

4989 Be 589.1.fid
Rusinov Be 589



3146.13.fid
Rusinov Be 589

—170.52

—157.82

—157.06

—155.85


—139.72

—128.97


—48.68


—21.03

—13.64



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:2.103(Scan#:802)

MassPeaks:132


RawMode:Single 2.103(802) BasePeak:277(6652995)

Фон.реж.:1.215(447) Group 1 - Event 1





7-Cyclopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19c)

Be 597.1.fid
Rusinov Be 597



3147.13.fid
Rusinov Be 597






Line#:1 R.Time:2.475(Scan#:951)

MassPeaks:160


RawMode:Single 2.475(951) BasePeak:275(2457363)

Фон.реж.:0.922(330) Group 1 - Event 1



7-Butyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19d)

1961 Be 721-2.1.fid
Rusinov Be 721/2



2011.13.fid
Rusinov Be 721/2

—171.00

158.31

158.25

157.77

—140.69

—129.63


—47.64

—30.85


19.62


14.13

13.97



¹³C, 100 MHz, DMSO-D₆






Line#:1 R.Time:4.677(Scan#:1832)

MassPeaks:149

RawMode:Single 4.678(1832) BasePeak:291(4338712)

Фон.реж.:2.640(1017) Group 1 - Event 1



7-Isobutyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19e)

4891.1.fid

Rusinov Be 587

8.99

4.00
3.98

2.80

2.25

2.23


2.21

2.19


2.18

1.00

0.99



¹H, 400 MHz, DMSO-D₆



3145.13.fid
Rusinov Be 587

—170.52


157.82
157.42

—140.20


—129.21


—53.79


27.31
19.35
13.63




^{13}C , 100 MHz, DMSO- D_6











Line#:1 R.Time:3.200(Scan#:1241)

MassPeaks:143

RawMode:Single 3.200(1241) BasePeak:291(3917519)

Фон.реж.:2.408(924) Group 1 - Event 1





3417 Be 790-F.13.fid
Rusinov Be 790/F

—170.53

157.86

157.82

157.33

—140.25

—129.19


—60.22

—47.44


—29.25

—25.31


—13.67



^{13}C , 100 MHz, DMSO- D_6



S53




Line#:1 R.Time:4.698(Scan#:1840)

MassPeaks:196


RawMode:Single 4.697(1840) BasePeak:307(959331)

Фон.реж.:2.845(1099) Group 1 - Event 1




Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	2.0 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	8.0 l/min
Scan End	1400 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
1	0.5	50059508	Manual	5377082	27792.5	EIC 308.0917±0.01 +All MS	308.0927	
2	0.8	124236288	Manual	3057557	1373.1	EIC 79.0213±0.01 +All MS	79.0212	

Cmpd 1, 0.5 min




#	Wavelength	Intensity
0	198	483.6
1	216	515.2
2	266	130.0
3	342	58.0




#	m/z	Res.	S/N	I	I %	FWHM
1	298.1082	28982	308252256.0	724348	17.5	0.0103
2	308.0927	35513	1765091712.0	4147707	100.0	0.0087
3	309.0949	24499	205099328.0	481953	11.6	0.0126
4	310.0899	18703	72333192.0	169972	4.1	0.0166
5	336.0871	22548	78992440.0	185621	4.5	0.0149
6	615.1779	39722	777050432.0	1825955	44.0	0.0155
7	616.1796	28876	205588656.0	483103	11.6	0.0213
8	617.1762	22376	90307312.0	212209	5.1	0.0276
9	922.2638	38041	202804592.0	476561	11.5	0.0242
10	923.2655	29853	88222328.0	207310	5.0	0.0309


7-(4-Chlorophenethyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6(7*H*)-one (19h)

214 Be 601.1.fid
Rusinov Be 601



3148.13.fid
Rusinov Be 601






Line#:1 R.Time:2.765(Scan#:1067)

MassPeaks:47


RawMode:Single 2.765(1067) BasePeak:138(6910195)

Фон.реж.:1.363(506) Group 1 - Event 1





7-Propyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,5-*a*]pyrimidin-6(7*H*)-one (20a)

070.1.fid
Rusinov KC-2163



2387.13.fid
Rusinov KC-2163






Line#:1 R.Time:2.265(Scan#:867)


MassPeaks:118

RawMode:Single 2.265(867) BasePeak:276(4987212)

Фон.реж.:0.990(357) Group 1 - Event 1



7-Isopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[5,1-*c*][1,5-*a*]pyrimidin-6(7*H*)-one (20b)



2388.13.fid
Rusinov KC-2164


—168.14
—158.23
—157.43
—155.45
—154.08
—148.77

—104.66


—48.13


—20.99

—13.41



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:2.143(Scan#:818)


MassPeaks:116

RawMode:Single 2.143(818) BasePeak:189(4904083)

Фон.реж.:0.828(292) Group 1 - Event 1



7-Cyclopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20c)



2389.13.fid
Rusinov KC-2166


168.26
159.43
157.72
157.44
153.81
148.82

104.39


30.20


13.40

5.79



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:2.560(Scan#:985)

MassPeaks:143

RawMode:Single 2.560(985) BasePeak:274(5699415)


Фон.реж.:1.718(648) Group 1 - Event 1




7-Butyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20d)

4901.1.fid

Rusinov KC-2158



¹H, 400 MHz, DMSO-D₆



2384.13.fid
Rusinov KC-2158

168.15
158.43
157.45
157.43
153.92
149.19

104.81


46.68

30.42


19.10


13.45

13.39



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:3.190(Scan#:1237)


MassPeaks:123


RawMode:Single 3.190(1237) BasePeak:290(3244138)


Фон.реж.:1.410(525) Group 1 - Event 1




7-Isobutyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20e)










S80




Line#:1 R.Time:2.510(Scan#:965)


MassPeaks:114


RawMode:Single 2.510(965) BasePeak:290(3749511)


Фон.реж.:2.132(814) Group 1 - Event 1



7-(4-Chlorophenethyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6(7*H*)-one (20h)








Line#:2 R.Time:39.008(Scan#:8763)

MassPeaks:120


RawMode:Averaged 39.004-39.013(8762-8764) BasePeak:138(73238)

Фон.реж.:Calc. from Peak Group 1 - Event 1




Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	2.0 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	8.0 l/min
Scan End	1400 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
1	0.6	23898960	Manual	3486000	30496.8	EIC 373.0619±0.005 +All MS	373.0635	
2	1.7	3216180	Manual	410657	93.8	EIC 321.0905±0.005 +All MS	321.0919	

Cmpd 1, 0.6 min




#	Wavelength	Intensity
0	192	79.3



#	m/z	Res.	S/N	I	I %	FWHM
1	198.0684	18519	22574452.0	55113	2.2	0.0107
2	339.1022	18707	10730792.0	26198	1.0	0.0181
3	373.0635	34093	1043798656.0	2548337	100.0	0.0109
4	374.0661	24225	176225632.0	430238	16.9	0.0154
5	375.0608	28133	353640320.0	863380	33.9	0.0133
6	376.0630	20786	63788436.0	155733	6.1	0.0181
7	377.0589	16404	16307131.0	39812	1.6	0.0230
8	767.1038	21648	15030682.0	36696	1.4	0.0354
9	769.1009	20089	11844270.0	28917	1.1	0.0383
10	1141.1643	21698	10243735.0	25009	1.0	0.0526

4-Amino-*N*-butyl-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazine-3-carboximidamide (21d).



2414 Be 613 - 13c.13.fid
Rusinov Be613

165.00

158.87

156.19

143.83

120.82


41.39

29.97


19.54


13.55

13.44



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:2.655(Scan#:1023)


MassPeaks:103


RawMode:Single 2.655(1023) BasePeak:233(489344)


Фон.реж.:2.283(874) Group 1 - Event 1




3-(Imino(morpholino)methyl)-7-(methylthio)-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-amine (21m).










S95




Line#:1 R.Time:2.237(Scan#:856)


MassPeaks:109


RawMode:Single 2.237(856) BasePeak:225(837487)


Фон.реж.:3.710(1445) Group 1 - Event 1



7-Amino-*N*-butyl-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboximidamide (22d)








Line#:1 R.Time:2.655(Scan#:1023)

MassPeaks:103


RawMode:Single 2.655(1023) BasePeak:233(489344)

Фон.реж.:2.283(874) Group 1 - Event 1




Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	3500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1400 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C




#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
1	1.6	459410560	Manual	18261930	29852.9	EIC 280.1325±0.005 +All MS	280.1343	

Cmpd 1, 1.6 min




#	Wavelength	Intensity
0	200	68.1
1	252	126.1



#	m/z	Res.	S/N	I	I %	FWHM
1	207.0445	19824	5890769.0	229479	1.5	0.0104
2	224.0713	21149	9368683.0	364964	2.3	0.0106
3	263.1069	21283	4699401.0	183068	1.2	0.0124
4	280.1343	14500	403645184.0	15724276	100.0	0.0193
5	281.1361	31020	81261704.0	3165606	20.1	0.0091
6	282.1307	25056	24125042.0	939808	6.0	0.0113
7	336.1962	26251	11103424.0	432542	2.8	0.0128
8	559.2595	28702	22831000.0	889397	5.7	0.0195
9	560.2615	21947	6767906.0	263648	1.7	0.0255
10	838.3871	24733	5159190.5	200980	1.3	0.0339

2-(Methylthio)-*N*-propylpyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23a)



1602.13.fid
Rusinov Be544


~168.84
~162.79
~158.98
~157.68

—139.80


—123.31


—42.60

~21.70
~13.55
~11.23



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:2.855(Scan#:1103)


MassPeaks:126

RawMode:Single 2.855(1103) BasePeak:276(7048154)

Фон.реж.:1.712(646) Group 1 - Event 1



N-Isopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23b)



1603.13.fid
Rusinov Be555

168.82
162.81
157.99
157.66


139.91

123.21


43.10


21.48

13.54



^{13}C , 100 MHz, DMSO- D_6






Line#1 R.Time:2.465(Scan#:947)


MassPeaks:115

RawMode:Single 2.465(947) BasePeak:276(6765279)

Фон.реж.:0.688(236) Group 1 - Event 1



N-Cyclopropyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23c)



1604.13.fid
Rusinov Be581

~168.87
~162.75
~160.08
~157.62


—139.65

—123.34


—24.98


—13.56

—5.87



¹³C, 100 MHz, DMSO-D₆






Line#:1 R.Time:1.900(Scan#:721)


MassPeaks:143

RawMode:Single 1.900(721) BasePeak:274(2593917)

Фон.реж.:3.190(1237) Group 1 - Event 1



N-Butyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23d)



1599.13.1.1r
Rusinov Be505

~168.88
~162.85
~158.95
~157.73

—139.85


—123.38

—40.63


—30.49


~19.56

~13.65
~13.59




^{13}C , 100 MHz, DMSO- D_6






S117



S118




Line#:1 R.Time:2.572(Scan#:990)

MassPeaks:144

RawMode:Single 2.572(990) BasePeak:290(5635427)

Фон.реж.:3.350(1301) Group 1 - Event 1



3295 Be 532.1.fid
Rusinov Be 532

—10.27 —8.60

3.54 3.52 2.79 2.18 2.17 2.15 2.13 2.12 1.01 0.99

CN1C=NC2=C(N1)N=CN=C2S3C=NC4=C(N3)N=CN=C4
23e
¹H, 400 MHz, DMSO-D₆

1.00 1.00 2.02 3.02 1.10 6.07

f1 (MД)

1601.13.fid
Rusinov Be532


168.82
162.70
159.14
157.69

139.85


123.38


48.23

27.65
20.05
13.55



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:1.763(Scan#:666)


MassPeaks:127

RawMode:Single 1.763(666) BasePeak:290(6816659)

Фон.реж.:0.425(131) Group 1 - Event 1



N-(*Tert*-butyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23f)



1600.13.1.1r
Rusinov Be525

~168.95
~162.00
~158.65
~157.70


—139.68

—123.34


—53.91


—28.28

—13.59



^{13}C , 100 MHz, DMSO- D_6







Line#:1 R.Time:1.492(Scan#:558)


MassPeaks:135


RawMode:Single 1.492(558) BasePeak:290(3501298)

Фон.реж.:2.555(983) Group 1 - Event 1










Line#:1 R.Time:2.632(Scan#:1014)


MassPeaks:114


RawMode:Single 2.632(1014) BasePeak:292(4061466)


Фон.реж.:2.380(913) Group 1 - Event 1



4-((2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)amino)butan-1-ol (23h)








Line#:1 R.Time:2.368(Scan#:908)


MassPeaks:196


RawMode:Single 2.368(908) BasePeak:306(1534400)


Фон.реж.:2.835(1095) Group 1 - Event 1




2-(Methylthio)-*N*-(*p*-tolyl)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23i)








Line#:1 R.Time:2.403(Scan#:922)
MassPeaks:120
RawMode:Single 2.402(922) BasePeak:277(3207225)
Фон.реж.:1.357(504) Group 1 - Event 1



N-(4-Chlorophenyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23j)



2073.13.1.1r


Rusinov Be 529 TE=50 Grad

168.24
162.40
157.52
157.36


139.75
136.23
129.24
128.35
124.77
123.13


40.15
39.94
39.73
39.52
39.31
39.10
38.90

13.48



¹³C, 100 MHz, DMSO-D₆






Line#:1 R.Time:2.830(Scan#:1093)


MassPeaks:169


RawMode:Single 2.830(1093) BasePeak:297(6882499)

Фон.реж.:1.490(557) Group 1 - Event 1




***N*-(4-Chlorophenethyl)-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (23k)**





S146




Line#:1 R.Time:3.018(Scan#:1168)


MassPeaks:131


RawMode:Single 3.018(1168) BasePeak:247(7281719)

Фон.реж.:1.130(413) Group 1 - Event 1




4-(2-((2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)amino)ethyl)phenol (23l)





S150




Line#:1 R.Time:3.005(Scan#:1163)


MassPeaks:81


RawMode:Single 3.005(1163) BasePeak:235(3146637)

Фон.реж.:1.423(530) Group 1 - Event 1





4-(2-(Methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-yl)morpholine (23m).






S154








Line#:1 R.Time:1.837(Scan#:696)

MassPeaks:145


RawMode:Single 1.837(696) BasePeak:304(6841278)


Фон.реж.:0.417(128) Group 1 - Event 1




2-(Methylthio)-6-(piperidin-1-yl)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazine (23n).

3483.1.fid
Rusinov Be 891/2








Line#:1 R.Time:1.603(Scan#:602)

MassPeaks:150


RawMode:Single 1.603(602) BasePeak:302(6498882)

Фон.реж.:3.268(1268) Group 1 - Event 1




Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	2.0 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	8.0 l/min
Scan End	1400 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
1	0.6	96468096	Manual	12909648	59569.2	EIC 303.1138±0.005 +All MS	303.1137	

Cmpd 1, 0.6 min




#	Wavelength	Intensity
0	192	83.8
1	256	46.0
2	408	21.3



#	m/z	Res.	S/N	I	I %	FWHM
1	303.1137	15899	670977984.0	9483236	100.0	0.0191
2	304.1155	33205	142157408.0	2009175	21.2	0.0092
3	305.1102	25729	40027480.0	565727	6.0	0.0119
4	325.0948	24102	22614914.0	319627	3.4	0.0135
5	341.0687	20234	6738350.5	95236	1.0	0.0169
6	605.2190	25534	16006233.0	226223	2.4	0.0237
7	627.2012	38875	129641488.0	1832282	19.3	0.0161
8	628.2032	30497	39065236.0	552127	5.8	0.0206
9	629.1996	23341	15705074.0	221967	2.3	0.0270
10	724.1348	23010	9027483.0	127590	1.3	0.0315

2-(Methylthio)-*N*-propylpyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24a)

4354.1.fid
Rusinov KC-2145/OC




2336.13.fid
Rusinov KC-2145

166.57
161.88
159.33
156.52
152.78
149.33


98.41

42.76


21.68
13.37
11.37



^{13}C , 100 MHz, DMSO- D_6



S165




Line#:1 R.Time:2.790(Scan#:1077)


MassPeaks:137

RawMode:Single 2.790(1077) BasePeak:275(4518060)

Фон.реж.:None Group 1 - Event 1



***N*-Isopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24b)**



2337.13.fid
Rusinov KC-2146



166.55
161.91
158.49
156.55
153.01
149.45

98.33


43.11

21.79

13.37



S169




Line#:1 R.Time:2.850(Scan#:1101)

MassPeaks:130

RawMode:Single 2.850(1101) BasePeak:275(4953572)


Фон.реж.:1.373(510) Group 1 - Event 1



N-Cyclopropyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24c)

4382.1.fid


Rusinov KC-2147/OC



2338.13.fid

Rusinov KC-2147

166.59
161.93
160.63
156.53
152.96
149.20




¹³C, 100 MHz, DMSO-D₆

98.53


24.67

13.38

6.10



S173




Line#:1 R.Time:2.595(Scan#:999)

MassPeaks:137


RawMode:Single 2.595(999) BasePeak:273(4378085)


Фон.реж.:1.523(570) Group 1 - Event 1





***N*-Butyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24d)**

3067.1.fid
Rusinov KC-2017/oc










S179




Line#:1 R.Time:2.432(Scan#:934)

MassPeaks:149


RawMode:Single 2.433(934) BasePeak:289(4675417)

Фон.реж.:1.357(504) Group 1 - Event 1



N-Isobutyl-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24e)

4159.1.fid
Rusinov KC-2141/OC





2335.13.fid
Rusinov KC-2141


166.57
161.85
159.57
156.56
152.88
149.39

98.46

48.36

27.58
20.16
13.37






Line#:1 R.Time:2.498(Scan#:960)


MassPeaks:145

RawMode:Single 2.498(960) BasePeak:289(4354368)


Фон.реж.:1.388(516) Group 1 - Event 1




N-(*Tert*-butyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24f)



S186






Line#:1 R.Time:2.340(Scan#:897)


MassPeaks:139


RawMode:Single 2.340(897) BasePeak:188(4455877)

Фон.реж.:0.765(267) Group 1 - Event 1




3-((2-(Methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-yl)amino)propan-1-ol (24g)





S191




Line#:1 R.Time:3.170(Scan#:1229)


MassPeaks:166


RawMode:Single 3.170(1229) BasePeak:291(623971)

Фон.реж.:2.650(1021) Group 1 - Event 1




4-((2-(Methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-yl)amino)butan-1-ol (24h)





S195




Line#:1 R.Time:4.960(Scan#:1945)

MassPeaks:159


RawMode:Single 4.960(1945) BasePeak:260(1164210)

Фон.реж.:4.345(1699) Group 1 - Event 1




Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	3500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1400 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C




#	RT [min]	Area	Int. Type	I	S/N	Chromatogram	Max. m/z	FWHM [min]
1	0.6	49257304	Manual	6647376	44584.3	EIC 306.1132±0.005 +All MS	306.1132	

Cmpd 1, 0.6 min




#	Wavelength	Intensity
0	192	92.7
1	260	33.3
2	342	13.1



#	m/z	Res.	S/N	I	I %	FWHM
1	306.1132	33974	536240448.0	4758054	100.0	0.0090
2	307.1156	24638	67519376.0	599099	12.6	0.0125
3	308.1104	18780	21182608.0	187953	4.0	0.0164
4	328.0947	20405	9678586.0	85878	1.8	0.0161
5	611.2195	29803	66112336.0	586614	12.3	0.0205
6	612.2216	22944	20257160.0	179742	3.8	0.0267
7	613.2182	19617	8664569.0	76881	1.6	0.0313
8	633.2011	22502	18168052.0	161205	3.4	0.0281
9	916.3267	28494	21172970.0	187867	3.9	0.0322
10	917.3287	24510	10441449.0	92647	1.9	0.0374

***N*-(4-Chlorophenethyl)-2-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (24k)**



2383.13.fid
Rusinov KC-2155

166.62
161.92
159.28
156.55
155.79
152.73
149.34

129.57
128.89


115.20

98.49


42.88


33.56

13.39



^{13}C , 100 MHz, DMSO- D_6







Line#:1 R.Time:3.553(Scan#:1382)

MassPeaks:127

RawMode:Single 3.553(1382) BasePeak:233(3234623)

Фон.реж.:2.507(964) Group 1 - Event 1





2382.1.fid
Risinov KC-2151


166.45
161.49
159.24
156.29
152.37
149.14
137.66
130.67
130.19
127.90

98.20


41.89


33.35

13.08



^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:3.735(Scan#:1455)

MassPeaks:84

RawMode:Single 3.735(1455) BasePeak:234(170300)


Фон.реж.:3.270(1269) Group 1 - Event 1



Ethyl 4-(((dimethylamino)methylene)amino)-7-(methylthio)-[1,2,4]triazolo[5,1-c][1,2,4]triazine-3-carboxylate (27a)

4014 Be 709.1.fid

Rusinov Be 709



2529 Be 742-13c.13.fid
Rusinov Be742

~169.09
~163.99
~160.22
~157.60

—140.99


—132.29

—61.29


—41.41

—34.91


~14.08
~13.46



^{13}C , 100 MHz, DMSO- D_6



S208




Line#:1 R.Time:2.237(Scan#:856)

MassPeaks:133

RawMode:Single 2.237(856) BasePeak:42(2653108)

Фон.реж.:0.897(320) Group 1 - Event 1




N'-(3-cyano-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4-yl)-*N,N*-dimethylformimidamide (27b)


3757 Be 701.1.fid
Rusinov Be 701

9.59

3.44
3.44
3.35
3.34
2.74



¹H, 400 MHz, DMSO-D₆



3307.13.fid
Rusinov Be 701/2


169.55
161.11
157.40

142.85


119.23
115.59


42.19
35.32

13.48



¹³C, 100 MHz, DMSO-D₆






Line#:1 R.Time:4.048(Scan#:1580)

MassPeaks:122


RawMode:Single 4.048(1580) BasePeak:262(5579360)

Фон.реж.:2.755(1063) Group 1 - Event 1



Ethyl 7-(((dimethylamino)methylene)amino)-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate (28a)

2606.1.1.1r
Rusinov KC-2228



2606.13.fid
Rusinov KC- 2228

166.77
164.53
159.11
157.36
156.36
152.17

102.33


60.58

40.60


34.58


13.96

13.28





^{13}C , 100 MHz, DMSO- D_6





S217






Line#:1 R.Time:2.720(Scan#:1049)


MassPeaks:152

RawMode:Single 2.720(1049) BasePeak:279(6476047)

Фон.реж.:1.670(629) Group 1 - Event 1



N'-(6-cyano-2-(methylthio)-[1,2,4]triazolo[1,5-*a*]pyrimidin-7-yl)-*N,N*-dimethylformimidamide (28b)



2612.13.fid
Rusinov KC-2268

167.39
159.87
157.46
156.46
151.11


115.75

87.29


41.36

34.61


13.10



^{13}C , 100 MHz, DMSO- D_6



S222




Line#:1 R.Time:1.995(Scan#:759)


MassPeaks:138

RawMode:Single 1.995(759) BasePeak:261(6989975)

Фон.реж.:0.760(265) Group 1 - Event 1



2-(Methylthio)-7-((morpholinomethylene)amino)-[1,2,4]triazolo[1,5-a]pyrimidine-6-carbonitrile (29).



2846.13.1.1r
Rusinov KC-2322

167.67
158.86
157.65
156.78
151.33

116.00


87.71

66.44
65.41

50.65


43.55


13.29




29


^{13}C , 100 MHz, DMSO- D_6





S227






Line#:1 R.Time:2.495(Scan#:959)


MassPeaks:191


RawMode:Single 2.495(959) BasePeak:303(1187910)

Фон.реж.:1.440(537) Group 1 - Event 1




4-Amino-*N*-butyl-7-(methylthio)-[1,2,4]triazolo[5,1-*c*][1,2,4]triazine-3-carboxamide (30d)







S232



S233



S234




Line#:1 R.Time:3.830(Scan#:1493)

MassPeaks:113

RawMode:Single 3.830(1493) BasePeak:281(3700897)


Фон.реж.:2.060(785) Group 1 - Event 1



***N*-Butylpyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (36).**

2609.1.1.1r


Rusinov KC-2004



S237

2609.13.1.1r
Rusinov KC- 2004

161.91
159.40
155.92
155.11
152.95
150.50



36

^{13}C , 100 MHz, DMSO- D_6


98.72


40.75

30.46

19.61

13.67






Line#:1 R.Time:1.958(Scan#:744)


MassPeaks:112

RawMode:Single 1.958(744) BasePeak:187(1295014)

Фон.реж.:2.240(857) Group 1 - Event 1



Ethyl 4-(butylamino)pyrazolo[1,5-*a*]pyrimido[5,4-*e*]pyrimidine-7-carboxylate (37).



2607.13.1.1r
Rusinov KC-2029

161.68
161.33
159.06
150.07
149.93
147.82
146.15

104.47
98.22

59.51


40.60

30.36

19.41


14.13


13.41



37

^{13}C , 100 MHz, DMSO- D_6






Line#:1 R.Time:3.413(Scan#:1326)


MassPeaks:124


RawMode:Single 3.413(1326) BasePeak:314(6209440)

Фон.реж.:2.408(924) Group 1 - Event 1




3-Butyl-4-imino-3,4-dihydropyrazolo[1,5-*a*]pyrimido[5,4-*e*]pyrimidine-7-carbonitrile (38).





S246




Line#:1 R.Time:2.557(Scan#:984)


MassPeaks:119

RawMode:Single 2.558(984) BasePeak:211(2228250)

Фон.реж.:1.482(554) Group 1 - Event 1



***N*-Butyl-2-methyl-5-(methylthio)pyrimido[5,4-*e*][1,2,4]triazolo[1,5-*a*]pyrimidin-6-amine (39).**



2611.13.fid
Rusinov KC-2068

164.50
163.98
160.08
158.64
154.15
149.79

97.44

41.54


30.33

19.62

14.68


14.14

13.66




39


^{13}C , 100 MHz, DMSO- D_6




S250



S251






Line#:1 R.Time:1.138(Scan#:416)

MassPeaks:198


RawMode:Single 1.138(416) BasePeak:214(734807)

Фон.реж.:4.508(1764) Group 1 - Event 1




N-Butyl-8-methyl-2-(methylthio)pyrimido[4,5-*e*][1,2,4]triazolo[5,1-*c*][1,2,4]triazin-6-amine (40).

1252 Be 722-2.1.fid
Rusinov Be 722/2



¹H, 400 MHz, DMSO-D₆




1729.13.fid
Rusinov Be 722/2

—173.41
—168.66
✓158.74
✓157.71


—139.88

—122.12


—40.38
~30.48
~27.21
✓19.53
✓13.63
✓13.57



^{13}C , 100 MHz, DMSO- D_6



S256



Line#:1 R.Time:1.825(Scan#:691)

MassPeaks:154

RawMode:Single 1.825(691) BasePeak:304(6102418)

Фон.реж.:0.738(256) Group 1 - Event 1

